var title_f24_26_24992="Orbital floor fracture entrapment";
var content_f24_26_24992=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F53238&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F53238&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Orbital blow-out fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 419px; height: 426px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A coronal computed tomogram demonstrates a fracture in the floor of the right orbit (black arrow). Entrapped orbital contents can be seen in the maxillary sinus (white arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mark Neuman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_26_24992=[""].join("\n");
var outline_f24_26_24992=null;
var title_f24_26_24993="Proplatelet processes EM";
var content_f24_26_24993=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F73160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F73160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Megakaryocyte proplatelet processes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scanning electron micrograph (x3000) shows the luminal view of the confluence of two bone marrow sinusoids with two proplatelet processes protruding through the lining endothelial cells. One of the processes has intermittent constrictions (arrows), indicating potential sites for platelet formation. Other cells depicted include lymphocytes and erythrocytes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Becker, RP, Bruyn, PPH. The transmural passage of blood cells into myeloid sinusoids and the entry of platelets into the sinusoidal circulation; A scanning electron microscopic investigation. Am J Anat 1975; 145:183. Copyright &copy; 1975 John Wiley &amp;Sons, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_26_24993=[""].join("\n");
var outline_f24_26_24993=null;
var title_f24_26_24994="Congenital TEF fluoro";
var content_f24_26_24994=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Congenital tracheoesophageal fistula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Congenital fistula visualized after aspiration of barium. A distal tracheoesophageal fistula connects the esophagus with the airway at the level of the carina.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_26_24994=[""].join("\n");
var outline_f24_26_24994=null;
var title_f24_26_24995="Acne conglobata face";
var content_f24_26_24995=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F55681&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F55681&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cystic acne conglobata",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 22-year-old man with a 2 year history of severe nodulocystic acne was treated with oral 13-cis retinoic acid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Yahia Albaili, DO, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_26_24995=[""].join("\n");
var outline_f24_26_24995=null;
var title_f24_26_24996="Minoxidil (systemic): Patient drug information";
var content_f24_26_24996=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Minoxidil (systemic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/38/11877?source=see_link\">",
"     see \"Minoxidil (systemic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/55/21364?source=see_link\">",
"     see \"Minoxidil (systemic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8774868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Loniten&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10029966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause very bad heart-related side effects. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702534",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to minoxidil or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703803",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Pheochromocytoma or a recent heart attack.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair growth.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12253 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-197.136.42.3-E9247BC0B9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_26_24996=[""].join("\n");
var outline_f24_26_24996=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774868\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029966\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029968\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029967\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029972\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029973\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029975\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029970\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029971\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029976\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029977\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/38/11877?source=related_link\">",
"      Minoxidil (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/55/21364?source=related_link\">",
"      Minoxidil (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/47/27379?source=related_link\">",
"      Minoxidil (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/58/33699?source=related_link\">",
"      Minoxidil (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_26_24997="Unilateral lung cancer PA";
var content_f24_26_24997=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67941&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67941&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Unilateral lymphangitic carcinomatosis in patient with lung cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 346px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph shows multiple left-sided, fine linear opacities that correspond to thickened interlobular septa of the lung parenchymal and subpleural interstitium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_26_24997=[""].join("\n");
var outline_f24_26_24997=null;
var title_f24_26_24998="Rifampin and other rifamycins";
var content_f24_26_24998=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rifampin and other rifamycins",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/26/24998/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/26/24998/contributors\">",
"     Richard H Drew, PharmD, MS, BCPS, FCCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/26/24998/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/26/24998/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/26/24998/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/26/24998/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/26/24998/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rifamycins include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/51/15160?source=see_link\">",
"     rifapentine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    . Of these, rifampin is most commonly used as first-line therapy (in combination with other agents) for treatment of mycobacterial infections, including tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24998/abstract/1\">",
"     1",
"    </a>",
"    ]. Rifapentine has a longer half-life than rifampin.",
"   </p>",
"   <p>",
"    Issues related to pharmacology of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/51/15160?source=see_link\">",
"     rifapentine",
"    </a>",
"    will be reviewed here. Issues related to clinical use of rifampin and rifapentine are discussed separately. (See related topics).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RIFAMPIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    is the most commonly used rifamycin for treatment of mycobacterial infections, in combination with other agents [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24998/abstract/1\">",
"     1",
"    </a>",
"    ]. It is also used for prophylaxis following exposure to Neisseria meningitidis or H. influenzae, and as an adjunctive agent for treatment of deep-seated staphylococcal infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    is thought to inhibit bacterial DNA-dependent RNA polymerase, which appears to occur as a result of drug binding in the polymerase subunit deep within the",
"    <span class=\"nowrap\">",
"     DNA/RNA",
"    </span>",
"    channel, facilitating direct blocking of the elongating RNA [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24998/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    arises due to missense mutations in the rpoB gene and occurs in a variety of bacteria including Mycobacterium tuberculosis, methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus pneumoniae, and Rickettsiae [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24998/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. Cross-resistance between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/51/15160?source=see_link\">",
"     rifapentine",
"    </a>",
"    depends on the mutation type.",
"   </p>",
"   <p>",
"    The rate of spontaneous resistance of M. tuberculosis via single-step mutation to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    is 1 in 10(8) bacilli [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24998/abstract/7\">",
"     7",
"    </a>",
"    ]. The rate of resistance in other types of bacteria (eg, Escherichia coli, S. aureus, Streptococcus spp, and N. meningitidis) is much higher [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24998/abstract/8\">",
"     8",
"    </a>",
"    ]. Since the rate of development of resistance is both high and predictable, rifampin is not used as monotherapy except for prophylaxis against N. meningitidis or H. influenzae.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Spectrum of in vitro activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracellular penetration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    is high, so rifampin is useful for treatment of intracellular pathogens. Its primary use (together with other agents) is in the treatment of M. tuberculosis infection, where it demonstrates bactericidal activity against most strains. Rifampin also has activity in vitro against atypical mycobacteria, including M. bovis and M. kansasii. Activity against Mycobacterium avium complex (MAC) organisms is variable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2441?source=see_link\">",
"     \"Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    also has in vitro activity against a broad spectrum of other bacteria although it is generally not used to treat these infections. Susceptible Gram positive organisms include S. aureus, coagulase-negative staphylococci, S. pyogenes, S. pneumoniae, viridans streptococci, and L. monocytogenes. Rifampin also has activity against Chlamydia spp. and diverse Gram negative pathogens, including Legionella spp., Brucella spp., H. influenzae, H. ducreyi, N. gonorrhoeae, and N. meningitidis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    undergoes rapid and complete absorption after oral administration. Absorption is improved when the oral dose is taken on an empty stomach. Rifampin undergoes wide distribution into most body tissues and fluids, including penetration into the cerebrospinal fluid. It concentrates intracellularly up to five times that of extracellular concentrations, primarily in polymorphonuclear leukocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24998/abstract/9\">",
"     9",
"    </a>",
"    ]. The protein binding of rifampin is approximately 80 percent.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    undergoes extensive hepatic metabolism to less active metabolites, with a half-life of three hours. Renal elimination of unchanged drug is minimal (&lt;30 percent); thus, no dose adjustments are required in patients with renal insufficiency. However, caution should be used when rifampin is administered to patients with significant hepatic disease, especially when used in combination with other hepatotoxins, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41943?source=see_link\">",
"     \"Isoniazid hepatotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dosing and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual adult dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    is 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (maximum 600 mg daily) (",
"    <a class=\"graphic graphic_table graphicRef50102 \" href=\"UTD.htm?23/25/23965\">",
"     table 1",
"    </a>",
"    ). Intravenous doses are similar to those administered orally. The usual pediatric dose range is 10 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, up to a maximum of 600 mg daily. Oral doses should be administered one hour before or two hours after meals. The therapeutic range for rifampin against M. tuberculosis is a two hour post-dose concentration of 8 to 24",
"    <span class=\"nowrap\">",
"     microgram/mL.",
"    </span>",
"   </p>",
"   <p>",
"    Higher",
"    doses for adults with prosthetic valve endocarditis due to methicillin-resistant S. aureus are up to 300 mg every eight hours for up to six weeks, in combination with other antistaphylococcal therapy. Reports of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    treatment for other staphylococcal infections generally utilize 600 mg per day (usually in two divided doses). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34712?source=see_link\">",
"     \"Antimicrobial therapy of prosthetic valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No dose adjustments are needed for renal dysfunction or dialysis. Although caution should be used in administering",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    to patients with underlying hepatic dysfunction, no formal guidelines are available to guide dosing in this population. However, it is known that metabolism may be significantly altered in patients with marked hepatic impairment. Twice- or three-times weekly directly observed therapy (DOT) regimens for tuberculosis utilize doses similar to those administered on a daily basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Special populations",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    has been safely administered during pregnancy. It is classified as pregnancy category C, meaning that the effects on the human fetus are unknown and teratogenicity has been demonstrated in laboratory animals. Therefore, it should be used only if potential benefits outweigh risks (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects associated with the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    include gastrointestinal effects (nausea, vomiting, diarrhea), central nervous system effects (headache, fever), dermatologic effects (rash, itching, flushing) and hematologic effects (thrombocytopenia and acute hemolytic anemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24998/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hepatitis is infrequently associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    and is more commonly observed in patients with predisposing factors, including administration of concomitant hepatotoxins such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    . A high incidence of hepatotoxicity has been observed in patients treated with a two month regimen of rifampin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    for latent tuberculosis infection, and for this reason subsequent guidelines have advised against use of this regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24998/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pruritus (with or without rash) can occur, but may not represent a true hypersensitivity reaction; as a result, continued use may be possible in some patients. Flu-like symptoms have been reported, especially in patients receiving intermittent therapy with higher doses. Patients should be advised that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    typically causes an orange or red-orange discoloration of body fluids (including sweat, saliva, and tears).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients must be educated about possible symptoms of hepatic toxicity, including unexplained anorexia, nausea, vomiting, dark urine, icterus, rash, pruritus, persistent fatigue, weakness or fever lasting three or more days, abdominal discomfort (particularly right upper quadrant discomfort), or easy bruising or bleeding. Arthralgias also can occur.",
"   </p>",
"   <p>",
"    Patients should be directly questioned at monthly visits for these symptoms. In addition, they should immediately report any signs or symptoms that occur between monthly visits. All patients with such complaints should be fully evaluated clinically, including serum testing for hepatic injury.",
"   </p>",
"   <p>",
"    Patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    as part of combination antituberculous therapy should undergo baseline evaluations of hepatic enzymes (aspartate aminotransferase, bilirubin, alkaline phosphatase), platelet count, and serum creatinine prior to the initiation of therapy.",
"   </p>",
"   <p>",
"    Repeated measurements should be obtained in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The baseline results are abnormal",
"     </li>",
"     <li>",
"      A drug reaction is suspected",
"     </li>",
"     <li>",
"      HIV infection",
"     </li>",
"     <li>",
"      Liver disease (eg, hepatitis B or C, alcohol abuse)",
"     </li>",
"     <li>",
"      Pregnancy or the first three months postpartum",
"     </li>",
"     <li>",
"      Patients receiving combination therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"       pyrazinamide",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Routine serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    concentration monitoring is not performed. However, the clinician must be aware of the many drug interactions that occur with rifampin therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug interactions result from the ability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    to induce the cytochrome P450 isoenzyme CYP3A4 (and to lesser extent CYP2C8 and CYP2C9), potentially decreasing serum concentrations of coadministered drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24998/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Such interactions include (but are not limited to) oral contraceptives, corticosteroids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    , azole antifungal agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ), oral hypoglycemics,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/9/10389?source=see_link\">",
"     mexiletine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    , beta-blockers, and HIV protease inhibitors (",
"    <a class=\"graphic graphic_table graphicRef57694 \" href=\"UTD.htm?0/14/238\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RIFAPENTINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/51/15160?source=see_link\">",
"     Rifapentine",
"    </a>",
"    has a longer half-life",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    . It has been shown to be safe but not significantly more active than a standard rifampin regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24998/abstract/14\">",
"     14",
"    </a>",
"    ]. Following completion of the initial phase of therapy for TB, in some circumstances rifapentine can be used in the continuation phase of treatment in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    in a once-weekly dosing regimen, thereby facilitating directly observed therapy. This regimen can be considered in HIV-negative patients without cavitary disease who were smear-negative at two months [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24998/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/51/15160?source=see_link\">",
"     Rifapentine",
"    </a>",
"    inhibits DNA-dependent RNA polymerase in susceptible strains of Mycobacterium tuberculosis. Rifapentine is bactericidal against both intracellular and extracellular M. tuberculosis organisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strains of M. tuberculosis resistant to other rifamycins including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    are likely to be resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/51/15160?source=see_link\">",
"     rifapentine",
"    </a>",
"    . Cross-resistance does not appear between rifapentine and other nonrifamycin antimycobacterial agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/51/15160?source=see_link\">",
"     Rifapentine",
"    </a>",
"    absorption is increased in the presence of food and rifapentine has high protein binding (97 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24998/abstract/16\">",
"     16",
"    </a>",
"    ]. The active metabolite is 25-desacetlyl rifapentine. Pharmacokinetic studies suggest that higher doses of the drug may be associated with higher concentrations of both free drug and metabolites [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24998/abstract/17\">",
"     17",
"    </a>",
"    ]. Most of the drug is eliminated in the feces (approximately 70 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/51/15160?source=see_link\">",
"     rifapentine",
"    </a>",
"    for adults is 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (600 mg) PO in a single dose given once weekly during the continuation phase of treatment (in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    ) by directly observed therapy (DOT) (",
"    <a class=\"graphic graphic_table graphicRef50102 \" href=\"UTD.htm?23/25/23965\">",
"     table 1",
"    </a>",
"    ). Limited data are available in children, but studies suggest the need for higher normalized weight-based dosing in order to achieve levels comparable to those in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24998/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Special populations",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/51/15160?source=see_link\">",
"     Rifapentine",
"    </a>",
"    is not recommended for use in patients with HIV infection because relapse associated with acquired",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    monoresistance was observed in six percent of cases in this population during pilot studies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24998/abstract/19\">",
"     19",
"    </a>",
"    ]. Rifapentine is also not recommended for children &lt;12 years, pregnant or lactating women, or for individuals with culture-negative or extrapulmonary tuberculosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/51/15160?source=see_link\">",
"     rifapentine",
"    </a>",
"    are mild and usually confined to the gastrointestinal tract (eg, nausea and vomiting) and hepatotoxicity. Hyperuricemia and elevations in liver function tests have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24998/abstract/20\">",
"     20",
"    </a>",
"    ]. Rifapentine, like other rifamycins, may produce an orange-red discoloration of body fluids (urine, tears, sputum, feces, and CSF). Contact lenses and dentures can become permanently stained [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24998/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with pre-existing hepatic problems should have liver function tests monitored every two to four weeks during therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/51/15160?source=see_link\">",
"     Rifapentine",
"    </a>",
"    , like other rifamycins, is a strong inducer of the cytochrome P450 (CYP) system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17082094\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rifamycins include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/51/15160?source=see_link\">",
"       rifapentine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"       rifabutin",
"      </a>",
"      . Of these, rifampin is most commonly used as first-line therapy (in combination with other agents) for treatment of mycobacterial infections, including tuberculosis. The rate of development of resistance to rifamycins is high; for this reason these agents are not used as monotherapy except for rifampin prophylaxis against N. meningitidis or H. influenzae. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       Rifampin",
"      </a>",
"      undergoes rapid and complete absorption after oral administration. Absorption is improved when the drug is administered orally on an empty stomach. Rifampin undergoes wide distribution into most body tissues and fluids, including penetration into the cerebrospinal fluid. Intracellular concentrations (primarily in polymorphonuclear leukocytes) are up to five times higher than extracellular concentrations. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pharmacokinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       Rifampin",
"      </a>",
"      undergoes extensive hepatic metabolism to less active metabolites, with a half-life of three hours. Renal elimination of unchanged drug is minimal (&lt;30 percent); thus, no dose adjustments are required in patients with renal insufficiency. However, caution should be used when rifampin is administered to patients with significant hepatic disease, especially when used in combination with other hepatotoxins, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pharmacokinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adverse effects associated with the administration of rifamycins include gastrointestinal, central nervous system, dermatologic and hematologic effects. Rifamycins may produce an orange-red discoloration of body fluids (urine, tears, sputum, feces, and spinal fluid. Hepatitis is infrequently associated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      and is more commonly observed in patients with predisposing factors, including administration of concomitant hepatotoxins such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      as part of combination antituberculous therapy should undergo baseline evaluations of hepatic enzymes (aspartate aminotransferase, bilirubin, alkaline phosphatase), platelet count, and serum creatinine prior to the initiation of therapy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients must be educated about possible symptoms of hepatic toxicity. Patients should be questioned regarding these symptoms at monthly visits and should report any signs or symptoms that occur between monthly visits. All patients should be fully evaluated clinically, including serum testing for hepatic injury. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/51/15160?source=see_link\">",
"       Rifapentine",
"      </a>",
"      has a longer half-life than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      . In some circumstances rifapentine can be used in the continuation phase of treatment (in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      ) in a once-weekly dosing regimen, thereby facilitating directly observed therapy. However rifapentine should not be used for patients with HIV infection, children &lt;12 years, pregnant or lactating women, or for individuals with culture-negative or extrapulmonary tuberculosis. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Rifapentine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Centers for Disease Control. Core Curriculum on Tuberculosis-1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24998/abstract/2\">",
"      Campbell EA, Korzheva N, Mustaev A, et al. Structural mechanism for rifampicin inhibition of bacterial rna polymerase. Cell 2001; 104:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24998/abstract/3\">",
"      Yuen LK, Leslie D, Coloe PJ. Bacteriological and molecular analysis of rifampin-resistant Mycobacterium tuberculosis strains isolated in Australia. J Clin Microbiol 1999; 37:3844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24998/abstract/4\">",
"      Wichelhaus TA, Sch&auml;fer V, Brade V, B&ouml;ddinghaus B. Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43:2813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24998/abstract/5\">",
"      Padayachee T, Klugman KP. Molecular basis of rifampin resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 1999; 43:2361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24998/abstract/6\">",
"      Drancourt M, Raoult D. Characterization of mutations in the rpoB gene in naturally rifampin-resistant Rickettsia species. Antimicrob Agents Chemother 1999; 43:2400.",
"     </a>",
"    </li>",
"    <li>",
"     Zhang Y, Vilcheze C, Jacobs WR. Mechanisms of drug resistance in Mycobacterium tuberculosis. In: Tuberculosis and the tubercle bacillus, ASM Press, Washington, DC 2005. p.125.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24998/abstract/8\">",
"      Farr B, Mandell GL. Rifampin. Med Clin North Am 1982; 66:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24998/abstract/9\">",
"      Mandell GL, Vest TK. Killing of intraleukocytic Staphylococcus aureus by rifampin: in-vitro and in-vivo studies. J Infect Dis 1972; 125:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24998/abstract/10\">",
"      Mart&iacute;nez E, Collazos J, Mayo J. Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions. Medicine (Baltimore) 1999; 78:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24998/abstract/11\">",
"      Centers for Disease Control and Prevention (CDC), American Thoracic Society. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24998/abstract/12\">",
"      Vesely JJ, Pien FD, Pien BC. Rifampin, a useful drug for nonmycobacterial infections. Pharmacotherapy 1998; 18:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24998/abstract/13\">",
"      Venkatesan K. Pharmacokinetic drug interactions with rifampicin. Clin Pharmacokinet 1992; 22:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24998/abstract/14\">",
"      Dorman SE, Goldberg S, Stout JE, et al. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J Infect Dis 2012; 206:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24998/abstract/15\">",
"      Munsiff SS, Kambili C, Ahuja SD. Rifapentine for the treatment of pulmonary tuberculosis. Clin Infect Dis 2006; 43:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24998/abstract/16\">",
"      Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001; 40:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24998/abstract/17\">",
"      CONWAY N, BIRT BD. STREPTOMYCIN IN PREGNANCY: EFFECT ON THE FOETAL EAR. Br Med J 1965; 2:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24998/abstract/18\">",
"      Blake MJ, Abdel-Rahman SM, Jacobs RF, et al. Pharmacokinetics of rifapentine in children. Pediatr Infect Dis J 2006; 25:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24998/abstract/19\">",
"      ROBINSON GC, CAMBON KG. HEARING LOSS IN INFANTS OF TUBERCULOUS MOTHERS TREATED WITH STREPTOMYCIN DURING PREGNANCY. N Engl J Med 1964; 271:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24998/abstract/20\">",
"      Jarvis B, Lamb HM. Rifapentine. Drugs 1998; 56:607.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 491 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-C88E1676B6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_26_24998=[""].join("\n");
var outline_f24_26_24998=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17082094\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RIFAMPIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Spectrum of in vitro activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dosing and administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Special populations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RIFAPENTINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Special populations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17082094\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/491\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/491|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/25/23965\" title=\"table 1\">",
"      Drug regimens for tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\" title=\"table 2\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/14/238\" title=\"table 3\">",
"      Rifamycin drug interactions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34712?source=related_link\">",
"      Antimicrobial therapy of prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41943?source=related_link\">",
"      Isoniazid hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2441?source=related_link\">",
"      Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=related_link\">",
"      Treatment of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_26_24999="Prenatal testing for the hemoglobinopathies and thalassemias";
var content_f24_26_24999=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prenatal testing for the hemoglobinopathies and thalassemias",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/26/24999/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/26/24999/contributors\">",
"     Brigitta U Mueller, MD, MHCM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/26/24999/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/26/24999/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/26/24999/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/26/24999/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/26/24999/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/26/24999/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hemoglobinopathies can be divided into two general types: the thalassemias (which are disorders of decreased globin chain production) and the hemoglobin variants (eg, sickle cell anemia and its variants, such as hemoglobin C disease), or a combination of the two. Hemoglobinopathies are chronic, debilitating, and often fatal. The severe clinical nature of these diseases is a primary stimulant for the development of fetal sampling and DNA-based diagnostic methodologies. Refinements in general care have improved the quality of life for these patients, but despite promising new therapies, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    , hematopoietic cell transplantation, and gene therapy, no curative regimen is available without some degree of morbidity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=see_link\">",
"     \"Specific therapies for sickle cell disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5529?source=see_link\">",
"     \"Efficacy of hematopoietic cell transplantation in beta thalassemia major\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The lack of effective treatment underscores the need for prenatal testing for sickle cell disease and thalassemia. This topic review will discuss the issues that must be faced by the parent and physician in making decisions about prenatal testing for inherited disorders of hemoglobin production and the",
"    <span class=\"nowrap\">",
"     sampling/testing",
"    </span>",
"    methods that may be used. The techniques of DNA-based testing are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/968?source=see_link\">",
"     \"Laboratory diagnosis of the hemoglobinopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sickle cell disease and thalassemia are among the most common genetic diseases worldwide. In a survey conducted by the World Health Organization, 71 percent of the 229 surveyed countries (representing 89 percent of all births worldwide) reported that hemoglobin disorders were a significant health problem [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24999/abstract/1\">",
"     1",
"    </a>",
"    ]. Over 330,000 infants are born annually with a hemoglobinopathy (83 percent with sickle cell disorders and 17 percent thalassemias). These disorders accounted for about 3.4 percent of deaths in children less than five years of age. Globally, around 7 percent of pregnant women are gene carriers of beta or alpha zero thalassemia, or hemoglobin (Hb) S, C, D Punjab or E; over 1 percent of couples are at risk for having an affected newborn.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     United States",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of individuals with sickle cell disease or sickle cell trait in the United States is unknown, but estimates range from 104,000 to 138,900 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24999/abstract/2\">",
"     2",
"    </a>",
"    ]. The frequency of carrier conditions for hemoglobinopathies is higher in blacks than in whites. Data obtained in California from 1990 to 1996 found that the genetic trait for sickle cell",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thalassemia occurred in 0.17 percent of non-Hispanic White births [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24999/abstract/3\">",
"     3",
"    </a>",
"    ]. By comparison, the gene frequency of sickling disorders is much higher in the black population: 4 percent for hemoglobin S, 1.5 percent for hemoglobin C, and 4 percent for beta-thalassemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24999/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the epidemiology of hemoglobinopathy, particularly thalassemia, is changing because of the introduction of new ethnic groups, some of whom are carriers of hemoglobinopathy, which had been rare in the United States, and the increasing admixture among different ethnicities within this country [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24999/abstract/3,5-7\">",
"     3,5-7",
"    </a>",
"    ]. This has led to the detection of hemoglobinopathies that previously had not been seen and involve infants from diverse ethnicities, thus, emphasizing the need for universal newborn screening in children of all ethnic backgrounds.",
"   </p>",
"   <p>",
"    These points are illustrated by data from the California newborn universal mandatory screening program for hemoglobinopathies that was initiated in 1990 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24999/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. Each year about 0.05 percent of the 530,000 newborn samples are sent to the Hemoglobin Reference Laboratory for confirmatory testing.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Between 1998 and 2006, sickle cell disease was the most common hemoglobinopathy (1 in 6600 births) followed by alpha-thalassemia (1 in 9000 births) and beta-thalassemia disease (1 in 55,000 births) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/26/24999/abstract/6\">",
"       6",
"      </a>",
"      ]. The confirmatory analysis modified the initial screening in 5 percent of cases and revealed 25 rare or new genotypes. Hemoglobin mutations were noted in infants from diverse ethnicities, including Southeast Asian, Black,",
"      <span class=\"nowrap\">",
"       Indian/Asian,",
"      </span>",
"      Middle Eastern, and Hispanic.",
"     </li>",
"     <li>",
"      In an earlier report of births from 1990 and 1996, the prevalence of sickle cell (all types) was highest in blacks at 1 per 396 births and was 1 per 36,000 births for Hispanics [",
"      <a class=\"abstract\" href=\"UTD.htm?24/26/24999/abstract/3\">",
"       3",
"      </a>",
"      ]. A shift of the at-risk groups for major beta thalassemias was noted with the majority of cases detected in families of Asian, Southeast Asian, and Asian Indian ancestry. In addition, Hb",
"      <span class=\"nowrap\">",
"       E/Beta,",
"      </span>",
"      a \"new\" hemoglobinopathy condition in California, was found almost exclusively in Southeast Asians with a prevalence of 1 in every 2600 births.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Global",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of hemoglobinopathy varies globally. The actual incidence in underdeveloped countries may be underreported because prenatal diagnosis relies upon technologically sophisticated methods (molecular diagnostic studies and hemoglobin electrophoresis), which are not available in areas with limited health resources. As the tools of reproductive genetics become more readily available, prenatal diagnosis of hemoglobinopathy may increase, which will aid in improving worldwide health care delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Thalassemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thalassemias occur in higher frequency in the Mediterranean area, the Middle East, Southeast Asia, Africa, and the Indian subcontinent. Extensive screening programs and prenatal diagnosis have resulted in a consistent decline in the birth of infants with beta-thalassemia in Mediterranean at-risk populations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24999/abstract/8\">",
"     8",
"    </a>",
"    ]. However, thalassemia remains a clinical problem in other parts of the world [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24999/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41783?source=see_link\">",
"     \"Community public health issues and the thalassemic syndromes: Lessons from other countries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Variations in the genotype of the heterozygotes result in differences in thalassemia phenotypes in the affected child [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24999/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      African- Americans may be heterozygous for both the beta thalassemia gene and sickle cell gene, since the two genes are closely linked. Alpha thalassemia minor in Africans most commonly consists of one gene for alpha globin synthesis missing on each chromosome 16. This deletion does not result in fetal sequelae.",
"     </li>",
"     <li>",
"      In contrast, the Southeast Asian pattern of alpha thalassemia minor consists of both genes missing from the same chromosome. If both parents have this pattern, offspring may have all four alpha globin genes absent and will be unable to synthesize any adult hemoglobins or hemoglobin F. This results in severe fetal anemia, high-output cardiac failure, hydrops fetalis, and death [",
"      <a class=\"abstract\" href=\"UTD.htm?24/26/24999/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36025?source=see_link\">",
"       \"Pathophysiology of alpha thalassemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Sickle cell disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The structural hemoglobin variants S and C are most common in tropical Africa but are also found in the Mediterranean area, Saudi Arabia, and Caribbean [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24999/abstract/1\">",
"     1",
"    </a>",
"    ]. Hemoglobin E is noted among Southeast Asians and may be the most common structural hemoglobin disorder in the world.",
"   </p>",
"   <p>",
"    In Africa, it has been estimated that 120,000 babies are born each year with sickle cell disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24999/abstract/6\">",
"     6",
"    </a>",
"    ] with a prevalence of sickle cell disease in the newborn population of 3 percent (2.8 percent SS and 0.2 percent SC) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24999/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RATIONALE FOR PRENATAL TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the hemoglobinopathies are autosomal recessive genetic disorders, parents who are heterozygote carriers of gene defects that affect the same globin chain have a 25 percent chance of having an offspring with a hemoglobinopathy. The risk of fetal hemoglobinopathy increases to 50 percent if one of the parents is homozygous for the genetic disorder and the other parent is a carrier. The availability of direct prenatal testing can provide at-risk couples a definite answer, rather than a statistical estimate, on whether the fetus has a hemoglobinopathy.",
"   </p>",
"   <p>",
"    The information from prenatal testing is used by the family to consider different reproductive options. Prenatal testing is often used by parents with an affected child during a subsequent pregnancy. &nbsp;However, prenatal diagnosis of a sickle hemoglobinopathy may also raise ethical dilemmas, since the clinical phenotype of the affected infant is difficult to predict [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24999/abstract/12\">",
"     12",
"    </a>",
"    ], and parental decisions strongly depend on the timing of the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24999/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most fetal cases with a known hemoglobinopathy, prenatal testing does not alter obstetrical care, as these genetic disorders in the fetus typically have no untoward effects on the mother and fetus. One exception is homozygous alpha thalassemia (also known as hydrops fetalis) with the loss of all four alpha globin chains, which usually results in fetal death during the late second through mid-third trimester of pregnancy. This may also be associated with maternal health risks of hypertension. The use of intrauterine transfusion has resulted in successful live births, sometimes at full term, although this intervention commits the infant to transfusion dependence. The prenatal diagnosis of this disorder allows the at-risk couple the option of considering intrauterine intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/57/13210?source=see_link&amp;anchor=H7#H7\">",
"     \"Intrauterine fetal transfusion of red blood cells\", section on 'Inherited RBC disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal diagnosis of sickle cell disease and thalassemia has been feasible for over 15 years. Its use is influenced by the ethical, cultural, and social background of the family. It is estimated that 50 to 70 percent of parents with sickle cell or thalassemia trait who have received genetic counseling request prenatal testing [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24999/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Genetic counseling'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    DNA-based testing for sickle cell, and alpha and beta thalassemia can be performed during the first trimester of pregnancy on villi obtained by chorionic villus sampling (typically performed at 10 to 12 weeks of gestation), or on cultured amniotic fluid cells obtained by amniocentesis (typically performed after 15 weeks of gestation) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24999/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. These procedures are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=see_link\">",
"     \"Diagnostic amniocentesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28169?source=see_link\">",
"     \"Chorionic villus sampling: Risks, complications, and techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One group has used ultrasound to measure the fetal cardiothoracic ratio and middle cerebral artery peak systolic velocity (MCA-PSV) to predict fetal homozygous alpha-thalassemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24999/abstract/18\">",
"     18",
"    </a>",
"    ]. Further study is needed to determine whether this examination can be used to avoid invasive testing in some patients.",
"   </p>",
"   <p>",
"    For some couples, preimplantation genetic diagnosis in combination with in vitro fertilization may be preferred to termination of an affected pregnancy. The advantage of preimplantation genetic diagnosis is that at-risk embryos can be identified and not transferred into the uterus, but the need for in vitro fertilization is a the major disadvantage of this approach. This approach has been successfully performed in couples who are thalassemic heterozygotes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24999/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=see_link\">",
"     \"In vitro fertilization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23431?source=see_link\">",
"     \"Preimplantation genetic diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Current research efforts are directed towards detecting point mutations in free fetal DNA sequences that are found in maternal plasma or serum [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24999/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. This promising technique will allow for noninvasive prenatal determination of fetal hemoglobinopathies, which will have a significant impact on parents' decision to undergo prenatal testing. However, at this time it is most useful for assessing paternally-inherited genes; it remains difficult to distinguish maternally-inherited fetal genes from maternal DNA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1448?source=see_link\">",
"     \"Prenatal diagnosis using cell-free fetal nucleic acids in maternal blood\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     WHO SHOULD BE TESTED",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing should be performed at the request of a couple who is at risk of having a fetus with hemoglobinopathy and who understands the risks and benefits of the procedure after receiving genetic counseling [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24999/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Identifying at-risk couples",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Routine prenatal care",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, the risk assessment for hemoglobinopathy was previously primarily based upon ethnic origin. However, because of the increasingly diverse ethnic and geographic distribution of hemoglobinopathy genotypes, risk assessment based on ethnic origin alone is not reliable [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24999/abstract/16\">",
"     16",
"    </a>",
"    ]. Routine prenatal care includes a comprehensive history that may identify at-risk parents. The history is most easily obtained by having the mother complete a questionnaire detailing her social, medical, and family history (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=see_link\">",
"     \"Initial prenatal assessment and patient education\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The following findings during routine prenatal care may be indicative of a pregnancy at-risk for hemoglobinopathy that requires further prenatal testing.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parent history &mdash; Parents may have a history of anemia. Mothers may have had a previous stillbirth.",
"     </li>",
"     <li>",
"      Family history &mdash; There may be a family history of a relative with a hemoglobinopathy or thalassemia. Couples from extended families living in endemic areas, and in which consanguineous marriages are common, may be at highest risk [",
"      <a class=\"abstract\" href=\"UTD.htm?24/26/24999/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Parents ethnic background &mdash; Ethnic groups that are at low risk for hemoglobinopathies are Northern Europeans, Japanese, Korean, Inuit (Eskimo), and Native Americans. Ethnic groups at high risk are of African, Southeast Asian, and Mediterranean ancestry. However, as discussed previously, given the increasing frequency of multi-ethnic couples, this risk stratification is becoming less relevant.",
"     </li>",
"     <li>",
"      Maternal red blood cell indices &mdash; All pregnant women should have a complete blood count (CBC) with red blood cell indices performed to screen for thalassemia [",
"      <a class=\"abstract\" href=\"UTD.htm?24/26/24999/abstract/16\">",
"       16",
"      </a>",
"      ]. An MCV &lt;80 fL in the absence of iron deficiency suggests thalassemia and further testing with hemoglobin electrophoresis is indicated [",
"      <a class=\"abstract\" href=\"UTD.htm?24/26/24999/abstract/24\">",
"       24",
"      </a>",
"      ]. CBC with red blood indices is easy to perform and readily available in countries with limited resources [",
"      <a class=\"abstract\" href=\"UTD.htm?24/26/24999/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link&amp;anchor=H22#H22\">",
"       \"Approach to the adult patient with anemia\", section on 'Microcytic anemia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Further evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;If routine prenatal care identifies findings that are suggestive of a risk of hemoglobinopathies, further evaluation of the parents is indicated. Hemoglobin electrophoresis confirms the carrier or homozygous status of both parents.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maternal hemoglobin electrophoresis &mdash; Hemoglobin electrophoresis identifies the presence of abnormal (eg, sickle cell variants) (",
"      <a class=\"graphic graphic_table graphicRef64715 \" href=\"UTD.htm?17/56/18316\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef68806 \" href=\"UTD.htm?8/51/9023\">",
"       image 1",
"      </a>",
"      ) and excess or deficient quantities of globin chains (eg, thalassemia) (",
"      <a class=\"graphic graphic_table graphicRef50393 \" href=\"UTD.htm?41/24/42380\">",
"       table 2",
"      </a>",
"      ). When abnormalities are noted, secondary tests such as DNA-based testing for alpha globin gene deletions may be required in order to establish a diagnosis.",
"     </li>",
"     <li>",
"      Paternal evaluation &mdash; If the results of the maternal hemoglobin electrophoresis demonstrate that the mother is either homozygous or a heterozygote carrier for hemoglobinopathy, an evaluation of the father is needed to assess fetal risk. This includes obtaining a paternal CBC and hemoglobin electrophoresis. As indicated above, a MCV&lt;80 fL in the absence of iron deficiency suggests thalassemia. Additionally, given the time constraints during prenatal care, initiation of the paternal evaluation with a CBC (including a MCV) and hemoglobin electrophoresis can provide valuable information for the couple's risk of an affected pregnancy. This can occur simultaneously with the maternal evaluation of hemoglobinopathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the setting where hemoglobin electrophoresis is performed first, some uncommon hemoglobins (eg, hemoglobins G, D, and Lepore) will migrate with the same mobility as hemoglobin S on electrophoresis at alkaline pH. These disorders do not sickle, and a solubility test may be helpful in making this distinction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42856?source=see_link\">",
"     \"Diagnosis of sickle cell syndromes\"",
"    </a>",
"    .) A solubility test, such as the Sickledex&reg;, only detects Hb S. If solubility testing is performed initially, it will identify individuals with HbSS, HbSC, and various combinations of sickle cell with alpha or beta thalassemia; however, hemoglobin electrophoresis would be required to differentiate among these conditions.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Genetic counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic counseling includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Review of the natural history of the genetic disorder",
"     </li>",
"     <li>",
"      Prospects for treatment",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cure",
"     </li>",
"     <li>",
"      Risk of having an affected child",
"     </li>",
"     <li>",
"      Availability of prenatal testing",
"     </li>",
"     <li>",
"      Management options for the parents based upon the results of prenatal testing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Genetic counseling for sickle cell disease is more difficult because of the uncertain prognosis and variable clinical severity of the disease. Clinical severity varies even within the most severe genotype (ie, homozygous sickle cell disease). Approximately 30 to 40 percent of patients with sickle cell anemia virtually never have pain, while others die or are incapacitated at a young age [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24999/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Counseling for sickle cell disease is further complicated by the lack of testable prognostic factors. The available DNA markers are not precise and need to be confirmed clinically. In addition, the presence of other gene mutations influences clinical heterogeneity in patients with sickle cell disease, as demonstrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Concurrent alpha thalassemia results in milder anemia, more frequent pain, and, in adult patients, a higher mortality rate. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39434?source=see_link&amp;anchor=H11#H11\">",
"       \"Clinical variability in sickle cell anemia\", section on 'Alpha thalassemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Certain beta-globin haplotypes correlate with the level of Hb F production that is a known modulator of severity in sickle cell disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39434?source=see_link&amp;anchor=H7#H7\">",
"       \"Clinical variability in sickle cell anemia\", section on 'Cis-acting elements'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The coexistence of the Central African Republic sickle cell haplotype and no alpha-thalassemia creates a high risk for morbidity and early death.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alpha thalassemias appear to be more complex [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24999/abstract/28\">",
"     28",
"    </a>",
"    ]; predictions of clinical severity in beta-thalassemia are more straightforward. The severity of these syndromes is inversely related to the amounts of Hb A and Hb F produced. The former is predictable from the specific mutation inherited [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/24999/abstract/29\">",
"     29",
"    </a>",
"    ], while the DNA markers determining the amount of Hb F are incompletely understood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38106?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the thalassemias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At the end of genetic counseling, the at-risk couple should be able to make an informed decision on whether to proceed with genetic testing and have an understanding on how the results of genetic testing will impact upon reproductive choices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/14/7394?source=see_link\">",
"       \"Patient information: Thalassemia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemoglobinopathies are divided into disorders of decreased globin chain production (thalassemia) and hemoglobin variants (sickle cell disease). These disorders are among the most common genetic diseases worldwide and can be chronic debilitating diseases that often are fatal. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prenatal genetic testing is available and provides at-risk couples a definite answer on whether the fetus has a hemoglobinopathy. This information can be used to help direct reproductive choices. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Rationale for prenatal testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      DNA-based testing for hemoglobinopathies can be performed during the first trimester of pregnancy on cells obtained by chorionic villus sampling (typically performed at 10 to 12 weeks of gestation), or on cultured amniotic fluid cells obtained by amniocentesis (typically performed after 15 weeks of gestation). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prenatal genetic testing should be made available to a couple who is at-risk of having a fetus with hemoglobinopathy, and who understands the risks and benefits of the procedure after receiving genetic counseling. At-risk couples (ie, heterozygote carriers) are identified by history and laboratory evaluation, including a complete blood count and hemoglobin electrophoresis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Who should be tested'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genetic counseling includes review of the natural history of the genetic disorder, prospects for treatment",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      care for an affected offspring, risks of having an affected child, the availability of prenatal testing, and management options based upon the test results. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Genetic counseling'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24999/abstract/1\">",
"      Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 2008; 86:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24999/abstract/2\">",
"      Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med 2010; 38:S512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24999/abstract/3\">",
"      Lorey FW, Arnopp J, Cunningham GC. Distribution of hemoglobinopathy variants by ethnicity in a multiethnic state. Genet Epidemiol 1996; 13:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24999/abstract/4\">",
"      Motulsky AG. Frequency of sickling disorders in U.S. blacks. N Engl J Med 1973; 288:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24999/abstract/5\">",
"      Pearson HA, Cohen AR, Giardina PJ, Kazazian HH. The changing profile of homozygous beta-thalassemia: demography, ethnicity, and age distribution of current North American patients and changes in two decades. Pediatrics 1996; 97:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24999/abstract/6\">",
"      Michlitsch J, Azimi M, Hoppe C, et al. Newborn screening for hemoglobinopathies in California. Pediatr Blood Cancer 2009; 52:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24999/abstract/7\">",
"      Vichinsky EP, MacKlin EA, Waye JS, et al. Changes in the epidemiology of thalassemia in North America: a new minority disease. Pediatrics 2005; 116:e818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24999/abstract/8\">",
"      Cao A, Saba L, Galanello R, Rosatelli MC. Molecular diagnosis and carrier screening for beta thalassemia. JAMA 1997; 278:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24999/abstract/9\">",
"      Vichinsky EP. Changing patterns of thalassemia worldwide. Ann N Y Acad Sci 2005; 1054:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24999/abstract/10\">",
"      Yong KN, Wadsworth D, Langlois S, et al. Thalassemia carrier screening and prenatal diagnosis among the British Columbia (Canada) population of Chinese descent. Clin Genet 1999; 55:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24999/abstract/11\">",
"      Odunvbun ME, Okolo AA, Rahimy CM. Newborn screening for sickle cell disease in a Nigerian hospital. Public Health 2008; 122:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24999/abstract/12\">",
"      Colah R, Surve R, Nadkarni A, et al. Prenatal diagnosis of sickle syndromes in India: dilemmas in counselling. Prenat Diagn 2005; 25:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24999/abstract/13\">",
"      Wang X, Seaman C, Paik M, et al. Experience with 500 prenatal diagnoses of sickle cell diseases: the effect of gestational age on affected pregnancy outcome. Prenat Diagn 1994; 14:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24999/abstract/14\">",
"      de Montalembert M, Guilloud-Bataille M, Ducros A, et al. Implications of prenatal diagnosis of sickle cell disease. Genet Couns 1996; 7:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24999/abstract/15\">",
"      Rowley PT, Loader S, Sutera CJ, et al. Prenatal screening for hemoglobinopathies. III. Applicability of the health belief model. Am J Hum Genet 1991; 48:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24999/abstract/16\">",
"      ACOG Committee on Obstetrics. ACOG Practice Bulletin No. 78: hemoglobinopathies in pregnancy. Obstet Gynecol 2007; 109:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24999/abstract/17\">",
"      Monni G, Zoppi MA, Axiana C, Ibba RM. Changes in the approach for invasive prenatal diagnosis in 35,127 cases at a single center from 1977 to 2004. Fetal Diagn Ther 2006; 21:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24999/abstract/18\">",
"      Leung KY, Cheong KB, Lee CP, et al. Ultrasonographic prediction of homozygous alpha0-thalassemia using placental thickness, fetal cardiothoracic ratio and middle cerebral artery Doppler: alone or in combination? Ultrasound Obstet Gynecol 2010; 35:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24999/abstract/19\">",
"      Kuliev A, Rechitsky S, Verlinsky O, et al. Preimplantation diagnosis of thalassemias. J Assist Reprod Genet 1998; 15:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24999/abstract/20\">",
"      Kuliev A, Rechitsky S, Verlinsky O, et al. Preimplantation diagnosis and HLA typing for haemoglobin disorders. Reprod Biomed Online 2005; 11:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24999/abstract/21\">",
"      Li Y, Di Naro E, Vitucci A, et al. Detection of paternally inherited fetal point mutations for beta-thalassemia using size-fractionated cell-free DNA in maternal plasma. JAMA 2005; 293:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24999/abstract/22\">",
"      Ho SS, Chong SS, Koay ES, et al. Noninvasive prenatal exclusion of haemoglobin Bart's using foetal DNA from maternal plasma. Prenat Diagn 2010; 30:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24999/abstract/23\">",
"      Ahmed S, Saleem M, Modell B, Petrou M. Screening extended families for genetic hemoglobin disorders in Pakistan. N Engl J Med 2002; 347:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24999/abstract/24\">",
"      Lafferty JD, Barth DS, Sheridan BL, et al. Prevalence of thalassemia in patients with microcytosis referred for hemoglobinopathy investigation in Ontario: a prospective cohort study. Am J Clin Pathol 2007; 127:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24999/abstract/25\">",
"      Sirichotiyakul S, Maneerat J, Sa-nguansermsri T, et al. Sensitivity and specificity of mean corpuscular volume testing for screening for alpha-thalassemia-1 and beta-thalassemia traits. J Obstet Gynaecol Res 2005; 31:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24999/abstract/26\">",
"      Steinberg MH. Predicting clinical severity in sickle cell anaemia. Br J Haematol 2005; 129:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24999/abstract/27\">",
"      Powars DR, Chan LS, Hiti A, et al. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine (Baltimore) 2005; 84:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24999/abstract/28\">",
"      Vichinsky E. Complexity of alpha thalassemia: growing health problem with new approaches to screening, diagnosis, and therapy. Ann N Y Acad Sci 2010; 1202:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/24999/abstract/29\">",
"      Kazazian HH Jr. The thalassemia syndromes: molecular basis and prenatal diagnosis in 1990. Semin Hematol 1990; 27:209.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 445 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-DB525E7F52-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_26_24999=[""].join("\n");
var outline_f24_26_24999=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      United States",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Global",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Thalassemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RATIONALE FOR PRENATAL TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      WHO SHOULD BE TESTED",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Identifying at-risk couples",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Routine prenatal care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Further evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Genetic counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/445\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/445|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/51/9023\" title=\"diagnostic image 1\">",
"      Hemoglobin electrophoresis at alkaline pH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/445|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/56/18316\" title=\"table 1\">",
"      Hgb electrophoresis patterns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/24/42380\" title=\"table 2\">",
"      Lab findings thalassemias",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28169?source=related_link\">",
"      Chorionic villus sampling: Risks, complications, and techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38106?source=related_link\">",
"      Clinical manifestations and diagnosis of the thalassemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39434?source=related_link\">",
"      Clinical variability in sickle cell anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41783?source=related_link\">",
"      Community public health issues and the thalassemic syndromes: Lessons from other countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42856?source=related_link\">",
"      Diagnosis of sickle cell syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=related_link\">",
"      Diagnostic amniocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5529?source=related_link\">",
"      Efficacy of hematopoietic cell transplantation in beta thalassemia major",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=related_link\">",
"      In vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=related_link\">",
"      Initial prenatal assessment and patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/57/13210?source=related_link\">",
"      Intrauterine fetal transfusion of red blood cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/60/968?source=related_link\">",
"      Laboratory diagnosis of the hemoglobinopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36025?source=related_link\">",
"      Pathophysiology of alpha thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/14/7394?source=related_link\">",
"      Patient information: Thalassemia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23431?source=related_link\">",
"      Preimplantation genetic diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1448?source=related_link\">",
"      Prenatal diagnosis using cell-free fetal nucleic acids in maternal blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=related_link\">",
"      Specific therapies for sickle cell disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_26_25000="Lipid abnormalities after cardiac transplantation";
var content_f24_26_25000=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lipid abnormalities after cardiac transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/26/25000/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/26/25000/contributors\">",
"     Howard J Eisen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/26/25000/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/26/25000/contributors\">",
"     Sharon A Hunt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/26/25000/contributors\">",
"     Mason W Freeman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/26/25000/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/26/25000/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/26/25000/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperlipidemia occurs in 60 to 83 percent of heart transplant recipients treated with modern, conventional immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. The abnormalities that occur include elevations in the serum levels of total and low density lipoprotein (LDL) cholesterol and in serum triglycerides (TG).",
"   </p>",
"   <p>",
"    The magnitude of these effects was illustrated in a study of 100 heart transplant recipients who survived more than three months after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/1\">",
"     1",
"    </a>",
"    ]. The following differences were noted between the baseline and three month values; there were no significant further increases over time:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Total cholesterol &mdash; 168 to 234",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4.4 to 6.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      LDL cholesterol &mdash; 111 to 148",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.9 to 3.8",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      HDL cholesterol &mdash; 34 to 47",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.9 to 1.2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Triglycerides &mdash; 107 to 195",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.2 to 2.2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar values have been noted in the control groups of randomized statin trials [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. In a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    trial, for example, the baseline and mean values during four year follow-up were [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Total cholesterol &mdash; 175 to 228",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4.5 to 5.9",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      LDL cholesterol &mdash; 109 to 156",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.8 to 4.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many heart transplant recipients had atherosclerotic heart disease as the etiology for heart failure and were often hyperlipidemic prior to transplantation, occasionally from genetic disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37274?source=see_link\">",
"     \"Inherited disorders of LDL-cholesterol metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, some patients, especially those with heart failure due to nonischemic causes such as idiopathic dilated cardiomyopathy, have a normal lipid profile prior to transplantation. De novo hyperlipidemia in these patients most often begins at two weeks and stabilizes three months after transplant unless there is further weight gain [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. A similar increase in lipid levels can occur in those with preexisting hyperlipidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of factors can contribute to posttransplant hyperlipidemia; these findings apply to both cardiac and renal transplantation. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Corticosteroids",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Male gender",
"     </li>",
"     <li>",
"      Renal insufficiency, which may be preexisting or develop after transplantation as a result of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Steroids are thought to play a major role in early posttransplant hyperlipidemia. They may act by leading sequentially to peripheral insulin resistance, hyperinsulinemia, and increased hepatic VLDL synthesis. The steroid-induced reduction in ACTH release also may contribute to the lipid abnormalities. In one report, the administration of ACTH for three weeks to nine hyperlipidemic. steroid-treated patients (five of whom were transplant recipients) led to substantial reductions in total and LDL-cholesterol and triglycerides, and an increase in HDL-cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/13\">",
"     13",
"    </a>",
"    ]. ACTH may act in part by upregulating LDL receptor activity.",
"   </p>",
"   <p>",
"    Several studies have documented the importance of corticosteroids, which is usually a function of the total steroid exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/3,11\">",
"     3,11",
"    </a>",
"    ]. In one study of renal transplant recipients, for example, steroid withdrawal was associated with a 17 percent reduction in total cholesterol levels [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/14\">",
"     14",
"    </a>",
"    ]. A similar effect has been noted in heart transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/11,15\">",
"     11,15",
"    </a>",
"    ]. One study compared 117 cardiac transplant recipients, 56 percent of whom were maintained of steroid-free immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/15\">",
"     15",
"    </a>",
"    ]. The mean serum cholesterol concentration during follow-up was 21 to 26 percent lower in those who did not receive steroids (average 205 versus 267",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [5.3 versus 6.9",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"   </p>",
"   <p>",
"    The net benefit of steroid withdrawal on atherosclerosis risk is uncertain. Although the fall in total cholesterol should be beneficial, it is associated with a proportionate and undesirable reduction in HDL-cholesterol levels [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/14,16\">",
"     14,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential importance of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    on lipid metabolism was illustrated by a study in renal transplant recipients in whom the total cholesterol level was 30 to 36",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.77 to 0.92",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    higher in patients treated with triple therapy including cyclosporine than in those receiving only",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/17\">",
"     17",
"    </a>",
"    ]. Cyclosporine may also raise the serum concentration of Lp(a) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/16\">",
"     16",
"    </a>",
"    ]. The effect of cyclosporine appears to be dose-dependent, since there is a rough correlation between blood cyclosporine levels and the degree of hypercholesterolemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    How the lipid changes occur is incompletely understood.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    is lipophilic and is transported in the blood in the core of low density and high density lipoprotein particles. It is possible, for example, that the alteration in LDL in some way interferes with its removal from the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/18\">",
"     18",
"    </a>",
"    ]. The effect of FK506 (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ) on lipid metabolism is similar to that of cyclosporine, although the rise in total cholesterol levels may be less pronounced [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies in renal transplant recipients are compatible with the importance of corticosteroids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . In one series, for example, the incidence of hypercholesterolemia fell from 38 percent in the first six months down to 13 percent at three years (when the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and cyclosporine doses were lower) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two important reasons for aggressive therapy of hyperlipidemia in the cardiac transplant recipient: prevention of progression of atherosclerosis in native vessels outside the heart; and slowing of the development of transplant vasculopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/25/44441?source=see_link\">",
"     \"Pathogenesis of and risk factors for cardiac allograft vasculopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since many heart transplant recipients have ischemic heart disease, there is a high likelihood of coexisting atherosclerotic disease in other vascular beds such as the cerebrovascular and peripheral arterial systems. Persistent hyperlipidemia may promote progression of atherosclerosis in these vessels.",
"   </p>",
"   <p>",
"    Treatment of hyperlipidemia in cardiac transplant recipients is similar to that in patients without transplants with the major exception being the issue of drug interactions between immunosuppressive agents and the lipid-lowering medications. Benefit may also be derived from dietary modification, exercise, and tight control of diabetes mellitus if present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Support for the clinical importance of lipid abnormalities after cardiac transplantation comes from two randomized trials showing improved clinical outcomes after statin therapy. The benefit from statins is also thought to be mediated by pleiotropic effects that are independent of lipid lowering. In transplant recipients, these include inhibition of inflammatory activity and cytokine activation, attenuation of endothelial dysfunction, and attenuation of vascular hypercoagulability [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/7,21-23\">",
"     7,21-23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=see_link\">",
"     \"Statins: Actions, side effects, and administration\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=see_link\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Clinical trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    therapy on clinical outcomes was evaluated in a randomized, prospective open-label trial of 97 heart transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/7\">",
"     7",
"    </a>",
"    ]. Pravastatin was begun at a dose of 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    one to two weeks after transplantation; if tolerated, the dose was increased to 40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    at one month. Pravastatin therapy was associated with the following significant benefits at one year compared to no statin therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A lower serum total cholesterol (193 versus 248",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [5.0 versus 6.4",
"      <span class=\"nowrap\">",
"       mmol/L]",
"      </span>",
"      in controls) and LDL cholesterol (116 versus 158",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [3.0 versus 4.1",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      and a higher HDL cholesterol (52 versus 43",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      <span class=\"nowrap\">",
"       [1/4",
"      </span>",
"      versus 1.1",
"      <span class=\"nowrap\">",
"       mmol/L]).",
"      </span>",
"     </li>",
"     <li>",
"      A higher survival rate (94 versus 78 percent) (",
"      <a class=\"graphic graphic_figure graphicRef66561 \" href=\"UTD.htm?27/41/28317\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A lower frequency of cardiac rejection episodes with hemodynamic compromise (6 versus 28 percent), suggesting some immunosuppressive activity [",
"      <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A lower incidence of transplant vasculopathy as determined by angiography or autopsy (6 versus 20 percent) and a lower maximal intimal thickness and intimal index on intracoronary ultrasonography. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/12/42184?source=see_link\">",
"       \"Prevention and treatment of cardiac allograft vasculopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ten year follow-up showed a persistent significant reduction in mortality (32 versus 52 reduction) and a reduced incidence of angiographic allograft vasculopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/24\">",
"     24",
"    </a>",
"    ]. These long-term benefits occurred even though 42 percent of the control group crossed over to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    during the second year of the study and 81 percent of control patients were eventually treated with a statin. Because of this crossover, serum cholesterol concentrations were similar in the two groups between two and ten years.",
"   </p>",
"   <p>",
"    Similar benefits were noted in a second prospective trial in which 72 heart transplant recipients were randomly assigned to active treatment with a low cholesterol diet plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    or general dietary therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/8\">",
"     8",
"    </a>",
"    ]. The target serum LDL cholesterol was 110 to 120",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.9 to 3.1",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    Simvastatin was started on the fourth postoperative day with dose adjustments at four and ten weeks to a maximum dose of 20",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    group had, at four year follow-up, the following significant benefits:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower total cholesterol (198 versus 228",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [5.1 versus 5.9",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      and LDL cholesterol (115 versus 156",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [3.0 versus 4.1",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"     </li>",
"     <li>",
"      Improved survival (89 versus 70 percent)",
"     </li>",
"     <li>",
"      A lower incidence of transplant vasculopathy (17 versus 42 percent)",
"     </li>",
"     <li>",
"      Although there was no difference in the incidence of graft rejections, serious rejection episodes tended to be less frequent (2.8 versus 13.5 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At four years, all the patients in the control arm were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    , and the entire cohort was followed for another four years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/25\">",
"     25",
"    </a>",
"    ]. At eight years, the patients in the original control arm continued to develop transplant vasculopathy at a more rapid rate (55 versus 24 percent) and had a lower survival rate (60 versus 89 percent) (",
"    <a class=\"graphic graphic_figure graphicRef60917 \" href=\"UTD.htm?30/59/31677\">",
"     figure 2",
"    </a>",
"    ). Thus, statin therapy initiated later after transplant was not sufficient to alter the effects of four years of progressive vasculopathy even though there was good lipid control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Side effects and drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A concern with statin therapy is the development of myopathy and possible rhabdomyolysis, particularly when given with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , which inhibit the CYP3A4 enzyme that metabolizes most statins. The risk is minimal with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    , which is",
"    <strong>",
"     not",
"    </strong>",
"    extensively metabolized by CYP3A4 and appears to have less intrinsic muscle toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. In addition, starting with a low statin dose substantially decreases the risk of muscle toxicity in heart transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/1,28-32\">",
"     1,28-32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=see_link\">",
"     \"Statin myopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=see_link\">",
"     \"Statins: Actions, side effects, and administration\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Fibric acid derivatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many cardiac transplant recipients have elevated triglycerides out of proportion to their cholesterol. Such patients can be treated with a fibric acid derivative, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7800?source=see_link\">",
"     \"Lipid lowering with fibric acid derivatives\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=see_link\">",
"     \"Approach to the patient with hypertriglyceridemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no randomized clinical trials evaluating fibrates in cardiac transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/33\">",
"     33",
"    </a>",
"    ]. The only evidence on outcomes comes from an observational study in which 137 patients were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    at the discretion of the physician [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/34\">",
"     34",
"    </a>",
"    ]. The mortality was significantly lower in the 56 patients receiving gemfibrozil (600 mg twice daily) compared to 22 untreated patients with high lipid levels (5 versus 27 percent) but not significantly lower than the 10 percent mortality rate in 59 untreated patients with normal lipid profiles. All patients received identical immunosuppressive therapy.",
"   </p>",
"   <p>",
"    Fibrates have been associated with muscle toxicity, an effect that is more pronounced in patients also treated with a statin. This effect may be mediated by competitive inhibition of CYP3A4, leading to a reduction in statin metabolism. In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    further inhibit CYP3A4; thus, the combination of a statin, a fibrate, and either of these agents is of particular concern and has been associated with rhabdomyolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=see_link\">",
"     \"Statin myopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As mentioned above,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    is not extensively metabolized by CYP3A4; as a result, it may be safer when combination therapy is required with a fibrate [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. However, the degree of protection is uncertain and the combination of a statin and a fibrate should be used with extreme caution, if at all, in heart transplant recipients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other drugs that can be used for lipid lowering are nicotinic acid, bile acid sequestrants, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/33\">",
"     33",
"    </a>",
"    ]. The characteristics of these drugs are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=see_link\">",
"     \"Lipid lowering with drugs other than statins and fibrates\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Nicotinic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nicotinic acid (niacin) lowers LDL cholesterol and triglycerides and raises HDL cholesterol. Its use is often limited by side effects, although the extended release preparation is often better tolerated. A particular issue in the transplant recipient is an elevation in liver enzymes when given in conjunction with immunosuppressive agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=see_link\">",
"     \"Lipid lowering with drugs other than statins and fibrates\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Bile acid sequestrants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bile acid sequestrants (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/26/12710?source=see_link\">",
"     colestipol",
"    </a>",
"    ) lower LDL and total cholesterol, but are associated with gastrointestinal toxicity and alter the absorption of fat soluble medications such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . As a result, initiation of therapy with these agents must be done with careful monitoring of cyclosporine levels [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/40\">",
"     40",
"    </a>",
"    ]. The introduction of the more readily absorbed and bioavailable cyclosporine microemulsion (Neoral) may limit the effects of bile acid sequestrants on cyclosporine [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Ezetimibe",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"     Ezetimibe",
"    </a>",
"    is not currently recommended in transplant recipients because of an interaction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    that can induce a 2 to 12 fold increase in ezetimibe levels and a supratherapeutic reduction in serum LDL cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/33,42\">",
"     33,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     LDL apheresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;LDL apheresis has been used in the treatment of familial hypercholesterolemia. Limited experience in heart transplant recipients with persistent hypercholesterolemia despite statin therapy suggests possible prevention or even regression of transplant vasculopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. However, these patients were not treated with the more powerful",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    . The main indication for consideration of this modality is statin-refractory hypercholesterolemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/5/10329?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of drug-resistant hypercholesterolemia\", section on 'LDL apheresis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Goal LDL cholesterol",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of lipid-lowering are not well defined in heart transplant recipients and the possible contribution of the pleiotropic (non-lipid-lowering) effects of statin therapy on the improvement in outcomes described above are not known. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Clinical trials'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=see_link\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite this uncertainty, we generally follow recommended guidelines for secondary prevention with goal LDL cholesterol of less than 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    of, in patients at very high risk, less than 70 to 80",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.8 to 2.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef82504 graphicRef67460 graphicRef54585 \" href=\"UTD.htm?16/27/16830\">",
"     table 1A-C",
"    </a>",
"    ). Because of the pleiotropic effects of statins, the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    regimen described below should be given even in patients with LDL cholesterol values at goal before therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/36/26179?source=see_link\">",
"       \"Patient information: Heart transplantation (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following general approach is recommended for the management of serum lipids in cardiac transplant recipients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The possible presence of baseline dyslipidemia should be determined prior to transplant.",
"     </li>",
"     <li>",
"      Diabetes mellitus should be aggressively controlled, especially once the patient's steroid dose is less than 10",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      This will be particularly beneficial for hypertriglyceridemia.",
"     </li>",
"     <li>",
"      Corticosteroids should be weaned to the lowest tolerated dose or be discontinued as early as is feasible and safe.",
"     </li>",
"     <li>",
"      All patients with hyperlipidemia pretransplant or who develop hyperlipidemia posttransplant should be placed on a low cholesterol diet such as the American Heart Association Step I and Step II diets.",
"     </li>",
"     <li>",
"      Transplant recipients should participate in a cardiac rehabilitation program in the early posttransplant period followed by a maintenance exercise program.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Hypercholesterolemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized clinical trials have shown that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    improve survival and reduce the incidence of acute rejection and transplant vasculopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/7,8,24,25\">",
"     7,8,24,25",
"    </a>",
"    ]. Pravastatin has the advantages of little or no muscle toxicity and, because it is not extensively metabolized by CYP3A4, limited drug interactions.",
"   </p>",
"   <p>",
"    All heart transplant recipients should be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    . Therapy is initiated at a dose of 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    within two weeks after transplantation; if tolerated, the dose is increased to 40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    at one month.",
"   </p>",
"   <p>",
"    If the goal LDL cholesterol is not achieved with a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    dose of 40",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    we suggest consideration of conversion to the more potent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    , with careful monitoring for myopathy. Although 80",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    is the usual maximum atorvastatin dose, doses above 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    have not been well studied in heart transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/33\">",
"     33",
"    </a>",
"    ]. The possible efficacy of adding the cholesterol absorption inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    is not proven and, as noted above, there is a potentially important interaction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=see_link\">",
"     \"Lipid lowering with drugs other than statins and fibrates\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most other statins are metabolized by CYP3A4, which can lead to potentially serious drug interactions with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    . Because of these interactions, it has been suggested that the daily dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    should not exceed 10 mg when used with cyclosporine or 20 mg when used with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/33,45\">",
"     33,45",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/33\">",
"     33",
"    </a>",
"    ]. The Food and Drug Administration (FDA) issued an alert warning against use of simvastatin greater than 20 mg per day in patients taking amiodarone due to the risk of rhabdomyolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/45\">",
"     45",
"    </a>",
"    ]. Combined therapy of a statin with fibric acid derivatives should be used with extreme caution due to potentiation of toxicity and myopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=see_link\">",
"     \"Statin myopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If maximal safe doses of a statin does not produce target LDL cholesterol concentrations, then a bile acid sequestrant or nicotinic acid can be added. A bile acid sequestrant is prescribed with a dosing interval four hours after ingestion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . As an example, we prescribe a bile acid sequestrant at lunch to avoid binding of cyclosporine and other agents. Cyclosporine levels should still be closely monitored.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"     Ezetimibe",
"    </a>",
"    is not currently recommended in transplant recipients because of an interaction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    that can induce a 2 to 12 fold increase in ezetimibe levels and a supratherapeutic reduction in serum LDL cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/33,42\">",
"     33,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Hypertriglyceridemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with persistent hypertriglyceridemia (= 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.26",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    can be treated with a fibric acid derivative such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/34\">",
"     34",
"    </a>",
"    ]. However, the combination of a statin and a fibrate should not be routinely used in heart transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/33\">",
"     33",
"    </a>",
"    ] because of the risk of severe myopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon limited data, fish oil (omega-3 polyunsaturated fatty acids) may be preferred for initial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/33,46\">",
"     33,46",
"    </a>",
"    ]. Pravastatin should be selected when a statin is combined with a fibric acid derivative [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]; serum cyclosporine levels and serum creatinine should be frequently monitored in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25000/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/1\">",
"      Ballantyne CM, Radovancevic B, Farmer JA, et al. Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations. J Am Coll Cardiol 1992; 19:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/2\">",
"      Becker DM, Markakis M, Sension M, et al. Prevalence of hyperlipidemia in heart transplant recipients. Transplantation 1987; 44:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/3\">",
"      Becker DM, Chamberlain B, Swank R, et al. Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients. Am J Med 1988; 85:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/4\">",
"      Stamler JS, Vaughan DE, Loscalzo J. Immunosuppressive therapy and lipoprotein abnormalities after cardiac transplantation. Am J Cardiol 1991; 68:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/5\">",
"      Taylor DO, Thompson JA, Hastillo A, et al. Hyperlipidemia after clinical heart transplantation. J Heart Transplant 1989; 8:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/6\">",
"      Rudas L, Pflugfelder PW, McKenzie FN, et al. Serial evaluation of lipid profiles and risk factors for development of hyperlipidemia after cardiac transplantation. Am J Cardiol 1990; 66:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/7\">",
"      Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/8\">",
"      Wenke K, Meiser B, Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 1997; 96:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/9\">",
"      Kubo SH, Peters JR, Knutson KR, et al. Factors influencing the development of hypercholesterolemia after cardiac transplantation. Am J Cardiol 1992; 70:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/10\">",
"      Laufer G, Grablowitz V, Laczkovics A, et al. The determinants of elevated total plasma cholesterol levels in cardiac transplant recipients administered low dose cyclosporine for immunosuppression. J Thorac Cardiovasc Surg 1992; 104:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/11\">",
"      Lake KD, Reutzel TJ, Pritzker MR, et al. The impact of steroid withdrawal on the development of lipid abnormalities and obesity in heart transplant recipients. J Heart Lung Transplant 1993; 12:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/12\">",
"      Stamler JS, Vaughan DE, Rudd MA, et al. Frequency of hypercholesterolemia after cardiac transplantation. Am J Cardiol 1988; 62:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/13\">",
"      Berg AL, Nilsson-Ehle P. ACTH lowers serum lipids in steroid-treated hyperlipemic patients with kidney disease. Kidney Int 1996; 50:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/14\">",
"      Hricik DE, Bartucci MR, Mayes JT, Schulak JA. The effects of steroid withdrawal on the lipoprotein profiles of cyclosporine-treated kidney and kidney-pancreas transplant recipients. Transplantation 1992; 54:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/15\">",
"      Renlund DG, Bristow MR, Crandall BG, et al. Hypercholesterolemia after heart transplantation: amelioration by corticosteroid-free maintenance immunosuppression. J Heart Transplant 1989; 8:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/16\">",
"      Hilbrands LB, Demacker PN, Hoitsma AJ, et al. The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. J Am Soc Nephrol 1995; 5:2073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/17\">",
"      Kasiske BL, Tortorice KL, Heim-Duthoy KL, et al. The adverse impact of cyclosporine on serum lipids in renal transplant recipients. Am J Kidney Dis 1991; 17:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/18\">",
"      Kuster GM, Drexel H, Bleisch JA, et al. Relation of cyclosporine blood levels to adverse effects on lipoproteins. Transplantation 1994; 57:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/19\">",
"      Steinm&uuml;ller TM, Gr&auml;f KJ, Schleicher J, et al. The effect of FK506 versus cyclosporine on glucose and lipid metabolism--a randomized trial. Transplantation 1994; 58:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/20\">",
"      Vathsala A, Weinberg RB, Schoenberg L, et al. Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients. Transplantation 1989; 48:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/21\">",
"      Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/22\">",
"      Weis M, Pehlivanli S, Meiser BM, von Scheidt W. Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation. J Am Coll Cardiol 2001; 38:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/23\">",
"      H&ouml;lschermann H, Hilgendorff A, Kemkes-Matthes B, et al. Simvastatin attenuates vascular hypercoagulability in cardiac transplant recipients. Transplantation 2000; 69:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/24\">",
"      Kobashigawa JA, Moriguchi JD, Laks H, et al. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant 2005; 24:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/25\">",
"      Wenke K, Meiser B, Thiery J, et al. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation 2003; 107:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/26\">",
"      Pfeffer MA, Keech A, Sacks FM, et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation 2002; 105:2341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/27\">",
"      Keogh A, Macdonald P, Kaan A, et al. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant 2000; 19:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/28\">",
"      Ballantyne CM, Bourge RC, Domalik LJ, et al. Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry. Am J Cardiol 1996; 78:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/29\">",
"      Carrier M, Pelletier GB, Genest J Jr, et al. Cholesterol-lowering intervention and coronary artery disease after cardiac transplantation. Ann Thorac Surg 1994; 57:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/30\">",
"      Barbir M, Rose M, Kushwaha S, et al. Low-dose simvastatin for the treatment of hypercholesterolaemia in recipients of cardiac transplantation. Int J Cardiol 1991; 33:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/31\">",
"      Kobashigawa JA, Murphy FL, Stevenson LW, et al. Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation 1990; 82:IV281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/32\">",
"      Vanhaecke J, Van Cleemput J, Van Lierde J, et al. Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine. Transplantation 1994; 58:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/33\">",
"      Bilchick KC, Henrikson CA, Skojec D, et al. Treatment of hyperlipidemia in cardiac transplant recipients. Am Heart J 2004; 148:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/34\">",
"      Stapleton DD, Mehra MR, Dumas D, et al. Lipid-lowering therapy and long-term survival in heart transplantation. Am J Cardiol 1997; 80:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/35\">",
"      Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/36\">",
"      Marais GE, Larson KK. Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy. Ann Intern Med 1990; 112:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/37\">",
"      Wiklund O, Angelin B, Bergman M, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 1993; 94:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/38\">",
"      Rosenson RS, Frauenheim WA. Safety of combined pravastatin-gemfibrozil therapy. Am J Cardiol 1994; 74:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/39\">",
"      Rader JI, Calvert RJ, Hathcock JN. Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med 1992; 92:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/40\">",
"      Keogh A, Day R, Critchley L, et al. The effect of food and cholestyramine on the absorption of cyclosporine in cardiac transplant recipients. Transplant Proc 1988; 20:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/41\">",
"      Mueller EA, Kovarik JM, van Bree JB, et al. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients--a concentration-controlled comparison with the commercial formulation. Transplantation 1994; 57:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/42\">",
"      Koshman SL, Lalonde LD, Burton I, et al. Supratherapeutic response to ezetimibe administered with cyclosporine. Ann Pharmacother 2005; 39:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/43\">",
"      Jaeger BR, Schirmer J, Thiery J, et al. Coronary risk factor management for the prevention and treatment of graft vessel disease in heart transplant patients. Ther Apher 1999; 3:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/44\">",
"      Park JW, Merz M, Braun P. Regression of transplant coronary artery disease during chronic low-density lipoprotein-apheresis. J Heart Lung Transplant 1997; 16:290.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Drugs/DrugSafety/ucm283137.htm (Accessed on January 03, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25000/abstract/46\">",
"      Durrington PN, Bhatnagar D, Mackness MI, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart 2001; 85:544.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3521 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-30319E2B35-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_26_25000=[""].join("\n");
var outline_f24_26_25000=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Statins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Side effects and drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Fibric acid derivatives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Nicotinic acid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Bile acid sequestrants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Ezetimibe",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - LDL apheresis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Goal LDL cholesterol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Hypercholesterolemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Hypertriglyceridemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3521\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3521|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/41/28317\" title=\"figure 1\">",
"      Pravastatin heart transplant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/59/31677\" title=\"figure 2\">",
"      Simvastatin heart transplant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3521|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/4/11340\" title=\"table 1A\">",
"      ATPIII LDL goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/46/10989\" title=\"table 1B\">",
"      Proposed ATPIII LDL goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/56/11147\" title=\"table 1C\">",
"      NCEP very high risk",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=related_link\">",
"      Approach to the patient with hypertriglyceridemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37274?source=related_link\">",
"      Inherited disorders of LDL-cholesterol metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=related_link\">",
"      Lipid lowering with drugs other than statins and fibrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7800?source=related_link\">",
"      Lipid lowering with fibric acid derivatives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=related_link\">",
"      Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/25/44441?source=related_link\">",
"      Pathogenesis of and risk factors for cardiac allograft vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/36/26179?source=related_link\">",
"      Patient information: Heart transplantation (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/12/42184?source=related_link\">",
"      Prevention and treatment of cardiac allograft vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=related_link\">",
"      Statin myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=related_link\">",
"      Statins: Actions, side effects, and administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/5/10329?source=related_link\">",
"      Treatment of drug-resistant hypercholesterolemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_26_25001="T cell receptor signaling";
var content_f24_26_25001=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"26\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   T cell receptor signaling",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/26/25001/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/26/25001/contributors\">",
"     Chaim M Roifman, MD, FRCPC, FCACB",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/26/25001/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/26/25001/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/26/25001/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/26/25001/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/26/25001/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H11026511\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;T cell recognition of antigen forms the basis of adaptive T cell immunity. Antigen is digested into peptides and bound to major histocompatibility complex (MHC) on the surface of antigen presenting cells for presentation to T cells. Recognition of self and foreign peptides by T cell receptor (TCR) complexes on immature thymocytes and mature T cells is necessary for the positive and negative selection of developing thymocytes and the functional responses of T cells. This topic briefly reviews signaling through the T cell receptor complex, identifying the proteins involved and highlighting downstream targets of the signaling cascade.",
"   </p>",
"   <p>",
"    T cell receptor genetics, structure, and biology are covered in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37733?source=see_link\">",
"     \"T cell receptor genetics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=see_link&amp;anchor=H4#H4\">",
"     \"The adaptive cellular immune response\", section on 'T cell activation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28329?source=see_link&amp;anchor=H2#H2\">",
"     \"CD3/T cell receptor complex disorders causing immunodeficiency\", section on 'Overview of T cell receptor biology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reviews related to combined immunodeficiencies caused by defects in TCR complex molecules are also presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28329?source=see_link\">",
"     \"CD3/T cell receptor complex disorders causing immunodeficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=see_link\">",
"     \"Combined immunodeficiencies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42022?source=see_link\">",
"     \"ZAP-70 deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11026518\">",
"    <span class=\"h1\">",
"     BRIEF OVERVIEW OF THE SIGNALING CASCADE",
"    </span>",
"    &nbsp;&mdash;&nbsp;T cell receptor (TCR) signaling in na&iuml;ve T cells is initiated by TCR binding to peptide-MHC complexes on the surface of antigen presenting cells. This engagement leads to a series of intracellular signaling events that culminate in the generation of a T cell response (",
"    <a class=\"graphic graphic_figure graphicRef66727 \" href=\"UTD.htm?20/20/20807\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Src-family protein tyrosine kinase Lck is first activated with resultant phosphorylation of CD3 coreceptor cytoplasmic domains, specifically at motifs known as immunoreceptor tyrosine-based activation motifs (ITAMs). These phosphorylated ITAMs on CD3&zeta; serve as binding sites for the zeta chain-associated protein kinase, ZAP-70. ZAP-70 is activated by Lck-mediated phosphorylation and subsequent autophosphorylation. Activated ZAP-70 then phosphorylates a variety of",
"    <span class=\"nowrap\">",
"     linker/adapter",
"    </span>",
"    proteins, such as linker for activation of T cells (LAT) and Src-homology 2 domain-containing 76-kDa leukocyte protein, SLP-76. Further signaling proteins are then recruited, resulting in calcium mobilization, actin cytoskeleton reorganization, and activation of Ras GTPases.",
"   </p>",
"   <p>",
"    Downstream from these events, there is activation of transcription factors, such as nuclear factor of activated T cells (NF-AT), activator protein 1 (AP-1), and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-&kappa;B), with resultant alterations in the pattern of T cell gene expression, proliferation and differentiation of effector function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11026525\">",
"    <span class=\"h1\">",
"     EARLY SIGNAL TRANSDUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The T cell receptor is a heterodimer, with approximately 95 percent of peripheral blood T cells expressing an alpha (&alpha;) and a beta (&beta;) chain. The &alpha; and &beta; chains of the TCR lack substantial cytoplasmic extensions and communicate with the interior of the cell through association with a group of single span transmembrane proteins known as the CD3 family. CD3 gamma (&gamma;), delta (&delta;), epsilon (&epsilon;), and zeta (&zeta;) form a complex with the TCR&alpha;&beta; receptor in a 1:1:2:2 ratio respectively for each TCR. In contrast to the TCR &alpha; and &beta; chains, the CD3 family members possess no known extracellular ligand binding capacity, but have long cytoplasmic tails that serve as frameworks for intracellular signaling. The antigen-bound",
"    <span class=\"nowrap\">",
"     TCR/CD3",
"    </span>",
"    complex lacks intrinsic catalytic activity and therefore initiation of signal transduction is critically dependent upon the activity of two protein tyrosine kinases: Lck and ZAP-70 (",
"    <a class=\"graphic graphic_figure graphicRef62164 \" href=\"UTD.htm?33/18/34083\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef66727 \" href=\"UTD.htm?20/20/20807\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/4-12\">",
"     4-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Failure to express any member of the CD3 family results in some degree of immunodeficiency, often severe. CD3&gamma; deficient patients typically have near normal T cell numbers, although with reduced",
"    <span class=\"nowrap\">",
"     TCR/CD3",
"    </span>",
"    complex expression, and show mild immunodeficiency. In contrast, complete CD3&epsilon;, CD3&delta;, and CD3&zeta; deficiencies typically display a T-B+(NK+) severe combined immunodeficiency (SCID). These all appear to result from an early block in T cell development. Partial deficiencies in expression of individual CD3 chains have been reported, typically with less severe immunodeficiency. Natural Killer (NK) cytotoxic function is also altered in CD3&zeta; deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28329?source=see_link&amp;anchor=H17#H17\">",
"     \"CD3/T cell receptor complex disorders causing immunodeficiency\", section on 'CD3 deficiency'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/0/10?source=see_link&amp;anchor=H6#H6\">",
"     \"Severe combined immunodeficiency (SCID): Specific defects\", section on 'CD3 complex component deficiencies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11026532\">",
"    <span class=\"h2\">",
"     Lck",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lck is a 56-kDa member of the Src-family tyrosine kinase family that is found constitutively associated with the cytoplasmic domain of the TCR coreceptors CD4 and CD8 (",
"    <a class=\"graphic graphic_figure graphicRef66727 \" href=\"UTD.htm?20/20/20807\">",
"     figure 1",
"    </a>",
"    ). It is activated rapidly following antigen binding to the TCR. Lck activity is absolutely required for normal T cell development and function.",
"   </p>",
"   <p>",
"    Lck has two critically important roles in the initiation of TCR signaling. The first is phosphorylation of the immunoreceptor tyrosine-based activation motifs (ITAMs) present in the cytoplasmic domains of the CD3 chains. These mediate interaction with other kinases (eg, CD3&epsilon; ITAM binds the Src family kinase Fyn, while ZAP-70 binds CD3&zeta;) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/13-19\">",
"     13-19",
"    </a>",
"    ]. The second is phosphorylation of ZAP-70 on multiple residues subsequent to its recruitment to phosphorylated CD3&zeta; chains, inducing activation of ZAP-70 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/13,18-20\">",
"     13,18-20",
"    </a>",
"    ]. In addition to its initiatory role in TCR signaling, Lck also has other functions further downstream in the signaling pathway: eg, phosphorylation of the",
"    <span class=\"nowrap\">",
"     Emt/Itk",
"    </span>",
"    kinase.",
"   </p>",
"   <p>",
"    Deficiency of Lck is reported to result in an immunodeficiency characterized by selective CD4 lymphopenia. Patients demonstrate the typical failure to thrive seen in SCID, opportunistic infections, and low to absent immunoglobulins. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28329?source=see_link&amp;anchor=H22#H22\">",
"     \"CD3/T cell receptor complex disorders causing immunodeficiency\", section on 'p56lck deficiency'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30009?source=see_link\">",
"     \"Idiopathic CD4+ lymphocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Lck protein is composed of a catalytic protein tyrosine kinase domain, a Src homology 2 (SH2) domain that recognizes phosphorylated tyrosine residues in the general context TyrXXLeu, and a Src homology 3 (SH3) domain that can bind proline rich motifs, generally with the pattern ProXProXXPro (where X equals any amino acid). Lck undergoes lipid modification during synthesis, with N-terminal myristoylation anchoring it to the inner leaflet of the T cell plasma membrane.",
"   </p>",
"   <p>",
"    There are two main tyrosine phosphorylation sites on Lck itself, residues 394 and 505. Tyr394 is an autophosphorylation site on the activation loop of the Lck catalytic domain, (Tyr394 phosphorylation results in Lck activation). Phosphorylation of the activation loop causes it to be repelled from the mouth of the catalytic site, enhancing substrate access. In contrast, Tyr505 undergoes negative regulatory phosphorylation by the c-Src kinase (Csk), leading to a &lsquo;closed&rsquo; conformation of Lck. The phosphorylated residue is bound by the Lck SH2 domain, folding up the protein into a conformation that blocks substrate access to the active site.",
"   </p>",
"   <p>",
"    The interplay between Tyr394 and Tyr505 phosphorylation in regulating Lck catalytic activity is complex. Modification of Tyr505 alone is insufficient to turn off Lck. Rather, phosphorylation of Tyr505 appears to merely shift the dynamic equilibrium between an open and closed conformation to favor more time spent in the closed state. Dephosphorylation of Tyr394 must also occur to completely downregulate Lck catalytic activity. To this end, the tyrosine phosphatase PTPN22 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/21\">",
"     21",
"    </a>",
"    ] is believed to act in a complex with Csk to regulate Lck (and other Src kinase family members). A variant allele of the PTPN22 phosphatase encoding an arginine to tryptophan alteration (R620W), relatively common in the Caucasian population, is linked to increased susceptibility to the development of autoimmunity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. The R620W allele of PTPN22 is a reported gain of function variant with increased catalytic activity that accelerates the downregulation of Lck activity subsequent to engagement of the T cell receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/22-27\">",
"     22-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Furthering the regulation of early signaling events, a transmembrane adaptor protein phosphoprotein-associated with glycosphingolipid microdomains",
"    <span class=\"nowrap\">",
"     (PAG/Cbp)",
"    </span>",
"    is basally tyrosine phosphorylated in resting human T cells and subsequently bound by the SH2 domain of Csk, maintaining Csk at the plasma membrane.",
"    <span class=\"nowrap\">",
"     PAG/Cbp",
"    </span>",
"    undergoes rapid dephosphorylation following TCR stimulation, with accompanying loss of Csk binding and recruitment to the membrane, permitting TCR signaling to proceed. Overexpression of PAG inhibits TCR-mediated responses. Cbp phosphorylation is regulated by the Src kinase family member Fyn [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early models of TCR signaling suggested that Lck was activated by interaction with the receptor tyrosine phosphatase CD45 following TCR recognition of",
"    <span class=\"nowrap\">",
"     antigen/MHC,",
"    </span>",
"    removing negative regulatory phosphorylation from the kinase. However, subsequent findings suggest that a large percentage of thymocytes and resting T cells already contain a large pool of preactivated Lck, priming them for a rapid response. Conformational changes releasing constraints on Lck, or changes promoting Lck interaction with CD3 cytoplasmic domains, are now believed to initiate signal transduction. Studies demonstrate a close electrostatic-based interaction between the unactivated CD3&epsilon; cytoplasmic domain and the inner leaflet of the plasma membrane, resulting in the insertion of key tyrosines into the lipid bilayer, potentially segregating them from Lck [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11026539\">",
"    <span class=\"h2\">",
"     ZAP-70",
"    </span>",
"    &nbsp;&mdash;&nbsp;An appreciation of the role of ZAP-70 in the biology of T cells and in TCR signaling came first from the description of a human deficiency of ZAP-70. This deficiency results in an unusual combined immunodeficiency where normal CD4+ T cells counts are present in the periphery, but CD8+ T cells absent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. ZAP-70 deficient thymi have normal architecture, but single-positive CD8+ cells are absent from the medulla [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/33\">",
"     33",
"    </a>",
"    ] due to a block between double-negative and double-positive cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/34\">",
"     34",
"    </a>",
"    ]. CD4+ peripheral T cells are nonfunctional and patients require hematopoietic stem cell replacement (ie, transplantation) to generate a functional T cell pool. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42022?source=see_link\">",
"     \"ZAP-70 deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ZAP-70 tyrosine kinase is recruited to the TCR complex following ITAM phosphorylation of the CD3&zeta; chain by Lck [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/16,17,35-38\">",
"     16,17,35-38",
"    </a>",
"    ]. ZAP-70 possesses tandem SH2 domains that bind the phosphorylated CD3&zeta; ITAM motif. ITAMs are four amino acid SH2 domain binding sequences,",
"    <span class=\"nowrap\">",
"     YXX(L/V),",
"    </span>",
"    that occur as a pair and are separated by a six to nine residue spacer region. Two SH2 domains were predicted in the ZAP-70 structure, but X-ray crystallographic analysis demonstrated that only one of these bound in the predicted manner, forming a specific pocket to enclose one of the phosphorylated tyrosine residues of CD3&zeta; [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/39\">",
"     39",
"    </a>",
"    ]. The second ZAP-70 SH2 domain formed an incomplete pocket, with atypical binding of the second phosphorylated tyrosine observed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following binding to CD3&zeta;, ZAP-70 undergoes phosphorylation at specific tyrosine residues, primarily by Lck, but also as the result of transautophosphorylation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/35,40-43\">",
"     35,40-43",
"    </a>",
"    ]. Much of the increase in ZAP-70 kinase activity following TCR stimulation is associated with the specific phosphorylation of Tyr493 in the activation loop of the ZAP-70 catalytic domain [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/40-43\">",
"     40-43",
"    </a>",
"    ], although the act of binding CD3&zeta; also causes conformational changes that increase activity. Binding to the phosphorylated CD3&zeta; ITAM may further serve to fully expose Lck regulatory phosphorylation sites.",
"   </p>",
"   <p>",
"    Phosphorylation of Tyr315 and Tyr319 within ZAP-70 also promotes TCR signal transduction by functioning as binding sites for downstream molecules: Tyr315 for the Vav guanine nucleotide exchange factor [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/44-46\">",
"     44-46",
"    </a>",
"    ] and Tyr 319 for phospholipase C&gamma; 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/44,47-49\">",
"     44,47-49",
"    </a>",
"    ], presumably directing access for their phosphorylation by the ZAP-70 kinase domain.",
"   </p>",
"   <p>",
"    ZAP-70 enzymatic activity is also negatively regulated by phosphorylation at Tyr492 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/40,41,50\">",
"     40,41,50",
"    </a>",
"    ]. Furthermore, phosphorylation of Tyr292 has been shown to downregulate ZAP-70 function by serving as a binding site for the ubiquitin ligase, Cbl. The E3-ubiquitin ligase Cbl modifies ZAP-70 through ubiquitylation of lysine residues, targeting it for proteasomal degradation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Cbl negatively regulates the activation of a number of TCR signal transducing proteins by inducing their degradation. ZAP-70 activity also appears to be downregulated as a result of the removal of activating tyrosine phosphorylation by cytoplasmic tyrosine phosphatases, including PTPN22 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11026546\">",
"    <span class=\"h1\">",
"     DISTAL CASCADE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Engagement of the",
"    <span class=\"nowrap\">",
"     TCR/CD3",
"    </span>",
"    complex by",
"    <span class=\"nowrap\">",
"     peptide/MHC",
"    </span>",
"    (pMHC) and subsequent activation of Lck and ZAP-70 kinases triggers a signaling cascade within the cell. This cascade culminates in the activation of pathways inducing transcription factor activity, with subsequent proliferation, differentiation, and cytokine secretion (",
"    <a class=\"graphic graphic_figure graphicRef66727 \" href=\"UTD.htm?20/20/20807\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The three major enzymatic pathways activated by T cell receptor ligation are the mitogen activated protein kinases (MAPK), the Rho family GTPases, and phosphoinositol regulated pathways. These pathways send signals into the nucleus via transcription factors, such as activator protein 1 (AP-1, dimer of Jun and Fos) and the nuclear factor of activated T cells (NF-AT).",
"   </p>",
"   <p>",
"    The downstream interactions result in signal amplification and culminate in the transcription of genes required for T cell activation and initiation of T cell-specific responses, such as CD69 upregulation and interleukin-2 (IL-2) secretion in mature na&iuml;ve T cells. The molecules and processes involved in the subsequent downstream cascade continue to be identified.",
"   </p>",
"   <p>",
"    ZAP-70-mediated tyrosine phosphorylation events are required for the mobilization of intracellular free calcium ([Ca2+]i) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/31\">",
"     31",
"    </a>",
"    ] and activation of the",
"    <span class=\"nowrap\">",
"     Ras/mitogen-activated",
"    </span>",
"    protein kinase (MAPK) and phosphatidylinositol-3 (PI-3) kinase pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/53-60\">",
"     53-60",
"    </a>",
"    ]. Specific substrates for ZAP-70 include the adaptor proteins linker for activation of T cells (LAT), and Src homology 2 (SH2) domain-containing 76-kDa leukocyte protein (SLP-76) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/6-10,48,53-58,61\">",
"     6-10,48,53-58,61",
"    </a>",
"    ]. Additional molecules that are recruited to the TCR via interactions with ZAP-70 or ZAP-70 substrates include Cbl, Vav, Grb-2, Sos, Gads, Itk, Ras-GAP, and the p85 subunit of PI-3 kinase [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/6-10,35,45,46,53-59,62\">",
"     6-10,35,45,46,53-59,62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11026553\">",
"    <span class=\"h2\">",
"     LAT",
"    </span>",
"    &nbsp;&mdash;&nbsp;ZAP-70 efficiently phosphorylates the integral membrane adaptor protein LAT. Phosphorylated LAT acts as a scaffold, promoting the interaction of a number of signal transducing proteins including the adaptor Grb2-related adaptor protein-2",
"    <span class=\"nowrap\">",
"     (GRAP2/GADS),",
"    </span>",
"    SLP76, IL-2 inducible T cell kinase (ITK), Grb2, p85 PI3-kinase and PLCgamma-1 (PLC&gamma;1). T cell development does not proceed beyond the earliest stages in the absence of LAT [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Palmitoylation during synthesis sequesters LAT into the lipid raft compartment of the plasma membrane.",
"   </p>",
"   <p>",
"    Grb2 binding to LAT serves to recruit Son of Sevenless (SOS), a guanine nucleotide exchange factor for the small GTPase Ras, leading to the activation of Ras and the MAPK cascade, with important roles in cellular activation and regulation of the cell cycle. The Ras guanyl nucleotide-releasing protein (RasGRP) is also recruited to the plasma membrane upon generation of diacylglycerol and activated by PKC&theta; mediated serine phosphorylation.",
"   </p>",
"   <p>",
"    SLP-76 is also an adaptor protein, recruiting ITK, Gads, Vav, and Nck to the LAT signalosome. In association with Vav, SLP-76 and LAT lead to activation of the Rho family of small GTPases, cdc42 and Rac1. These function in cytoskeletal reorganization. SLP-76 and LAT also link the TCR to activation of phosphatidylinositol 3' kinase (PI-3kinase). PI3-kinase modifies membrane phosphatidylinositol (PtdIns) lipids, phosphorylating the 3&rsquo; position hydroxyl group of the inositol ring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11026560\">",
"    <span class=\"h2\">",
"     Lipid and lipid derived messengers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generation of 3&rsquo;-phosphorylated-inositol lipids in the plasma membrane can create binding sites for signaling molecules possessing a PtdIns-binding pleckstrin homology (PH) domain, including the cytoplasmic expressed in mast and T",
"    <span class=\"nowrap\">",
"     cells/IL-2",
"    </span>",
"    inducible T cell tyrosine kinase",
"    <span class=\"nowrap\">",
"     (Emt/Itk)",
"    </span>",
"    that is recruited to the membrane following TCR activation.",
"    <span class=\"nowrap\">",
"     Emt/Itk",
"    </span>",
"    also binds the membrane adapter LAT via its SH2 domain, after phosphorylation of LAT by ZAP-70.",
"    <span class=\"nowrap\">",
"     Emt/Itk",
"    </span>",
"    is subsequently activated via Lck-mediated tyrosine phosphorylation.",
"    <span class=\"nowrap\">",
"     Emt/Itk-deficient",
"    </span>",
"    mice display compromised phospholipase C gamma 1 (PLC&gamma;1) phosphorylation and reduced extracellular calcium flux in response to TCR stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/65-69\">",
"     65-69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PI3-kinase activity is also responsible for PH domain-dependent recruitment of PLC&gamma;1 in response to TCR engagement through the generation of phosphatidylinositol(3,4,5)trisphosphate in the plasma membrane. SLP-76 and LAT also link to the PLC&gamma;1 pathway. PH domain-mediated docking to the plasma membrane also recruits phosphoinositide dependent kinase 1 (PDK1) and its substrate Akt (also called protein kinase B,PKB), activating this survival promoting pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PLC&gamma;1 cleaves phosphatidylinositol(4,5)bisphosphate into diacylglycerol (DAG) and inositol triphosphate (IP3). Membrane bound DAG activates members of the protein kinase C family, in particular PKC&theta;, which plays important roles in activation of Ras and the transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells (NF-&kappa;B). In unstimulated cells, NF-&kappa;B is sequestered to the cytoplasm by interaction with the inhibitor of &kappa;B (I&kappa;B). NF-&kappa;B activation requires I&kappa;B degradation. In a signal cascade, DAG-activated PKC&theta; phosphorylates the IkB kinase IKK, which in turn phosphorylates IkB, causing its ubiquitination and subsequent degradation, freeing NFkB to translocate into the nucleus. DAG also recruits rasGRP to the membrane where the guanine release factor undergoes PKC&theta; mediated activating phosphorylation and helps activate the Ras signaling pathway.",
"   </p>",
"   <p>",
"    Soluble IP3 mobilizes calcium from intracellular storage sites by binding to IP3 receptors on the surface of the endoplasmic reticulum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11026567\">",
"    <span class=\"h2\">",
"     Calcium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sustained elevation of cytosolic levels of free calcium (Ca2+) plays a critical role in promoting TCR signaling. Several hours of Ca2+ influx are required to complete T cell activation. In particular, elevated Ca2+ maintains prolonged nuclear accumulation of NFAT by activating the phosphatase calcineurin, which dephosphorylates the cytoplasmic form of the transcription factor NFAT, allowing it to enter the nucleus and initiate transcription.",
"   </p>",
"   <p>",
"    Store-operated Ca2+ entry is used by many types of cells, including lymphocytes, to increase intracellular Ca2+ concentrations to initiate signal transduction [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/72\">",
"     72",
"    </a>",
"    ]. Activation of the TCR results in an IP3-dependent release of Ca2+ ions from endoplasmic reticulum (ER) Ca2+ stores. Depletion of Ca2+ from this internal store subsequently leads to the opening of plasma membrane ion channels allowing an influx of external Ca2+.",
"   </p>",
"   <p>",
"    Stromal interaction molecule 1 (STIM1) expressed in the ER senses ER calcium ion levels and is responsible for triggering Ca2+ release-activated Ca2+ (CRAC) channels. Patients with STIM1 mutations abrogating STIM1 expression (and subsequently Ca2+ influx) present with many immune defects including, immunodeficiency, hepatosplenomegaly, autoimmune hemolytic anemia, and thrombocytopenia. Studies of STIM1 deficient mice suggest STIM1-dependent store-operated Ca2+ entry is critical for homeostatic T cell proliferation, but less important for T cell differentiation or effector function [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=see_link&amp;anchor=H10#H10\">",
"     \"Combined immunodeficiencies\", section on 'ORAI1/CRACM1 and STIM1 deficiencies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mutations in ORAI1, the gene encoding the pore-forming subunit of the Ca2+-release&ndash;activated Ca2+ (CRAC) channel, abrogate the store-operated entry of Ca2+ into cells and also impair lymphocyte activation. In humans, ORAI1 deficiency presents with normal lymphocyte counts and serum immunoglobulin levels but is characterized by recurrent infections, impaired T-cell activation and proliferative responses, and decreased production of cytokines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=see_link&amp;anchor=H10#H10\">",
"     \"Combined immunodeficiencies\", section on 'ORAI1/CRACM1 and STIM1 deficiencies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11026574\">",
"    <span class=\"h2\">",
"     Actin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activation of the",
"    <span class=\"nowrap\">",
"     Vav/Rho",
"    </span>",
"    family signaling pathway leading to rearrangement of the actin cytoskeleton plays a critical role in sustaining the T cell signaling response. TCR activation typically occurs upon encounter with antigen loaded major histocompatibility complex on antigen presenting cells. At this point, the T cell undergoes a transition from a highly motile cell in an antigen presenting cell (APC) scanning mode, to one favoring relatively stable interactions. TCR engagement leads to the rapid formation of filamentous actin, required for polarization or reorientation of the T cell towards the stimulating cell [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Effective T cell response appears dependent upon the formation of a highly spatially ordered interface between the T cell and APC referred to as the immunologic synapse (IS) or supramolecular activation cluster (SMAC) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]. This structure is composed of concentric rings each containing specific receptors and signaling proteins. As examples, the",
"    <span class=\"nowrap\">",
"     TCR/CD3",
"    </span>",
"    complex and associated signaling proteins cluster into a &ldquo;central supramolecular activation cluster&rdquo; (c-SMAC), while LFA-1 integrin is found in a peripheral SMAC (p-SMAC) that forms a ring of adhesion between the cells. The maintenance of an intact immunologic synapse for many hours appears to be required for the effective activation of the T cell, although the identity of the particular APC (eg, dendritic cell, macrophage, B cell) may significantly affect requirements. The stable synapse may also provide a focal point for focused secretion and endocytosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25432?source=see_link\">",
"     \"Antigen presenting cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TCR signaling induced rearrangement of the actin cytoskeleton plays a critical role in decreasing T cell motility, in the molecular segregation of the T cell surface receptors, and in spatial organization of intracellular signaling components. Even prior to the formation of the mature immunologic synapse, activated",
"    <span class=\"nowrap\">",
"     TCR/CD3",
"    </span>",
"    complexes form microclusters that localize into the c-SMAC in a process dependent upon actin polymerization. Thus, early signaling events prepare the platform for sustained distal signaling and T cell responses. Evidence suggests that the cSMAC have an active TCR signaling zone and a TCR downregulating zone that uses ubiquitination machinery. PKC&theta; and Wiskott&ndash;Aldrich syndrome protein (WASp) activity critically regulate synapse stability. Immunologic synapses are hyperstable in PKC&theta; deficient T cells, while they are unstable in WASp deficient cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Wiskott&ndash;Aldrich syndrome, or WASp deficiency, is an X-linked immunodeficiency in humans characterized by increased susceptibility to infections, eczema, thrombocytopenia, and decreased antibody production. Patients also display autoimmune disease and an increased incidence of malignancy, although the type of",
"    <em>",
"     WAS",
"    </em>",
"    mutation correlates significantly with the degree of disease severity. WASp-deficient T cells show impaired proliferation and actin rearrangement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36313?source=see_link\">",
"     \"Wiskott-Aldrich syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TCR-mediated activation of T cell adhesion molecules such as LFA-1 is also critical to immunologic synapse formation. The mechanism by which inside-out signaling to activate LFA-1 operates is unclear, but involves activation of the Rac GTP exchange factor (GEF) Vav and the Rap1 GEF, C3G. Rap1 may be recruited to the plasma membrane by the",
"    <span class=\"nowrap\">",
"     ADAP/SKAP55",
"    </span>",
"    adapter protein complex.",
"   </p>",
"   <p>",
"    For a more detailed review of TCR signaling kinetics at the synapse, see [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11026581\">",
"    <span class=\"h1\">",
"     TCR SIGNALING IN T CELL ONTOGENY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     TCR/CD3",
"    </span>",
"    complex is not only absolutely required for the proper function of mature T cells, but also plays a significant role in T cell ontogeny (",
"    <a class=\"graphic graphic_figure graphicRef76102 \" href=\"UTD.htm?21/33/22047\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early in the differentiation of the thymocyte, genomic DNA encoding one of the TCR&beta; chains undergoes physical rearrangement to create a functional gene in a process known as V(D)J recombination. This is dependent upon recombinase activating genes 1 and 2 (RAG1 and RAG2) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Failure to correctly rearrange the TCR&beta; locus as a result of defective RAG enzyme activity, results in severe combined immunodeficiency that often presents as Omenn syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20362?source=see_link\">",
"     \"T cell negative, B cell negative, NK cell positive severe combined immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differentiating thymocyte identifies functional rearrangement of the TCR&beta; gene by its ability to signal. The rearranged TCR&beta; chain associates with an invariant preTCR&alpha; (pT&alpha;) chain to form an active pre-TCR complex with CD3 chains that is hypothesized to signal in a non-ligand-dependent manner. This may be due to a high potential for self-multimerization, conferring autonomous signaling [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. Signaling through the pre-TCR complex involves many of the same proteins critical to mature T cell TCR signaling including ZAP-70, LAT, Lck, Fyn, and PLC&gamma;1, although their relative importance may vary [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/83-86\">",
"     83-86",
"    </a>",
"    ]. Pre-TCR signals promote thymocyte survival and proliferation, expression of CD4 and CD8 coreceptors, rearrangement of TCR&alpha;, and also induce a process known as allelic exclusion, whereby rearrangement of the second TCR&beta; allele is prevented. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37733?source=see_link\">",
"     \"T cell receptor genetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    T cell precursors in the thymus with correctly rearranged TCR &alpha; and &beta; chains undergo positive and negative selection processes before they mature into CD4+ or CD8+ T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/87\">",
"     87",
"    </a>",
"    ]. The fate of these cells is determined in large part by the interaction of the",
"    <span class=\"nowrap\">",
"     TCR/CD3",
"    </span>",
"    complex with self-antigens presented by thymic epithelial cells. Strong interaction, and as a result a",
"    <span class=\"nowrap\">",
"     prolonged/high",
"    </span>",
"    level of TCR signaling in the thymocyte, indicates there is the potential for autoreactivity and these cells are deleted (negative selection). A weak to moderate interaction between the thymocyte and self-antigen presenting epithelial cells allows the cells to mature (positive selection). Levels of phosphorylated (activated) ZAP-70 and MAPK activation have been identified as critical signaling events linked to the selection process. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CD3 or TCR chain deficiency may prevent the proper interaction of the precursors with the thymic epithelium, therefore eliminating the selection process. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28329?source=see_link\">",
"     \"CD3/T cell receptor complex disorders causing immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A failure to negatively select or delete self-recognizing cells because of failure to express self antigens in the thymus results in multisystem autoimmunity, as observed in AIRE transcription factor deficiency that causes autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22553?source=see_link&amp;anchor=H571991#H571991\">",
"     \"Chronic mucocutaneous candidiasis\", section on 'Autoimmune regulator (AIRE) deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11026588\">",
"    <span class=\"h2\">",
"     Syk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syk is a 72-kDa molecule with significant homology to ZAP-70. Expressed predominantly in B cells and myeloid cells, Syk is also found in thymocytes and at low levels in some mature T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/90\">",
"     90",
"    </a>",
"    ]. It is critical to B cell receptor (BCR) signaling and functions in B cells in a manner fairly analogous to ZAP-70 in T cells. In murine thymocytes, Syk plays a role in TCR signaling. Syk binds phosphorylated ITAMs and can be activated by pre-TCR and TCR stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/5,13,91\">",
"     5,13,91",
"    </a>",
"    ]. Analysis of mice deficient in both Syk and ZAP-70 demonstrated that Syk is critical to early pre-TCR signaling in CD4- CD8- double-negative thymocytes and may induce ZAP-70 expression required for subsequent thymocyte selection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/83-85,92-94\">",
"     83-85,92-94",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42022?source=see_link\">",
"     \"ZAP-70 deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11026595\">",
"    <span class=\"h2\">",
"     Themis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thymocyte-expressed molecule involved in selection (Themis), is a protein of unknown function that is highly conserved among vertebrates. It is highly expressed in thymocytes between the pre-T cell antigen receptor and positive-selection checkpoints, with lower expression in mature T cells. Themis-deficient mice have few thymocytes, with a defect in positive selection, resulting in fewer mature thymocytes. Themis undergoes rapid tyrosine phosphorylation that is dependent upon LAT and SLP-76 and interacts with LAT, PLC&gamma;1, Grb2 and ITK. The precise role of Themis in TCR signaling is still unclear, but T cells lacking THEMIS gene expression demonstrate reduced IL-2 expression following TCR stimulation as a result of reduced ERK and",
"    <span class=\"nowrap\">",
"     NFAT/AP-1",
"    </span>",
"    signaling. Evidence suggests Themis is required for optimal calcium mobilization and MAPK activation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/81,95,96\">",
"     81,95,96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11026602\">",
"    <span class=\"h1\">",
"     NK CELL SIGNALING",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in T cells, some of the activating receptors expressed by natural killer (NK) cells possess ITAMs that when phosphorylated can recruit ZAP-70 or Syk kinases to the plasma membrane for initiation of downstream signaling events [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/82,97,98\">",
"     82,97,98",
"    </a>",
"    ]. ZAP-70 function is not absolutely required for human NK cell differentiation or cytotoxicity in vivo, unlike T cell ontogeny [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/82,97,99\">",
"     82,97,99",
"    </a>",
"    ]. However, Syk may be critical for NK function, at least in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?24/26/25001/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42022?source=see_link&amp;anchor=H24434181#H24434181\">",
"     \"ZAP-70 deficiency\", section on 'Pathogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30889?source=see_link\">",
"     \"NK cell deficiency syndromes: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/39/4724?source=see_link\">",
"     \"NK cell deficiency syndromes: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11026609\">",
"    <span class=\"h1\">",
"     CORECEPTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not discussed above, the coligation or activation of TCR coreceptors such as CD4, CD8, CD28, CTLA-4, and other receptors such as LFA-1 can dramatically affect the final outcome of the TCR signaling cascade through the ability of these receptors to reinforce or inhibit the activation of signal transducing proteins in specific pathways. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11026616\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Engagement of the T cell receptor with peptide bound to the major histocompatability complex expressed on antigen presenting cells leads to a series of events that culminate in the generation of T cell responses (",
"      <a class=\"graphic graphic_figure graphicRef66727 \" href=\"UTD.htm?20/20/20807\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11026511\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11026518\">",
"       'Brief overview of the signaling cascade'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial transduction of antigen-binding signals from the",
"      <span class=\"nowrap\">",
"       TCR/CD3",
"      </span>",
"      complex is primarily dependent upon two protein tyrosine kinases: Lck and ZAP-70 (",
"      <a class=\"graphic graphic_figure graphicRef66727 \" href=\"UTD.htm?20/20/20807\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11026525\">",
"       'Early signal transduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Activation of early signaling molecules triggers a distal cascade in the cell culminating in the activation of pathways that induce transcription factors, with subsequent proliferation, differentiation, and cytokine secretion responses. Three main pathways activated by T cell ligation are the mitogen activated protein kinases (MAPK), the Rho family GTPases, and phosphoinositol regulated pathways. (See",
"      <a class=\"local\" href=\"#H11026546\">",
"       'Distal cascade'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       TCR/CD3",
"      </span>",
"      complex is mandatory for the proper function of mature T cells and also plays a significant role in T cell ontogeny (",
"      <a class=\"graphic graphic_figure graphicRef76102 \" href=\"UTD.htm?21/33/22047\">",
"       figure 3",
"      </a>",
"      ). The processes involved in CD4 versus CD8 selection during T cell ontogeny require signal transduction through the pre-TCR and TCR of the differentiating thymocyte. The signaling events mediated by the pre-TCR and TCR on thymocytes are similar to those responsible for the activation of mature T cells. (See",
"      <a class=\"local\" href=\"#H11026581\">",
"       'TCR signaling in T cell ontogeny'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"       \"Normal B and T lymphocyte development\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      ZAP-70 function is not absolutely required for natural killer (NK) cell differentiation or cytotoxicity. However, Syk may be critical for NK function. (See",
"      <a class=\"local\" href=\"#H11026602\">",
"       'NK cell signaling'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/1\">",
"      Love PE, Hayes SM. ITAM-mediated signaling by the T-cell antigen receptor. Cold Spring Harb Perspect Biol 2010; 2:a002485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/2\">",
"      Abraham RT, Weiss A. Jurkat T cells and development of the T-cell receptor signalling paradigm. Nat Rev Immunol 2004; 4:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/3\">",
"      Huang Y, Wange RL. T cell receptor signaling: beyond complex complexes. J Biol Chem 2004; 279:28827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/4\">",
"      Weiss A, Littman DR. Signal transduction by lymphocyte antigen receptors. Cell 1994; 76:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/5\">",
"      Cheng AM, Chan AC. Protein tyrosine kinases in thymocyte development. Curr Opin Immunol 1997; 9:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/6\">",
"      Wange RL, Samelson LE. Complex complexes: signaling at the TCR. Immunity 1996; 5:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/7\">",
"      Kane LP, Lin J, Weiss A. Signal transduction by the TCR for antigen. Curr Opin Immunol 2000; 12:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/8\">",
"      Qian D, Weiss A. T cell antigen receptor signal transduction. Curr Opin Cell Biol 1997; 9:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/9\">",
"      van Leeuwen JE, Samelson LE. T cell antigen-receptor signal transduction. Curr Opin Immunol 1999; 11:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/10\">",
"      van Oers NS. T cell receptor-mediated signs and signals governing T cell development. Semin Immunol 1999; 11:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/11\">",
"      Zamoyska R, Basson A, Filby A, et al. The influence of the src-family kinases, Lck and Fyn, on T cell differentiation, survival and activation. Immunol Rev 2003; 191:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/12\">",
"      Palacios EH, Weiss A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 2004; 23:7990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/13\">",
"      van Oers NS, Weiss A. The Syk/ZAP-70 protein tyrosine kinase connection to antigen receptor signalling processes. Semin Immunol 1995; 7:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/14\">",
"      Gauen LK, Zhu Y, Letourneur F, et al. Interactions of p59fyn and ZAP-70 with T-cell receptor activation motifs: defining the nature of a signalling motif. Mol Cell Biol 1994; 14:3729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/15\">",
"      Irving BA, Chan AC, Weiss A. Functional characterization of a signal transducing motif present in the T cell antigen receptor zeta chain. J Exp Med 1993; 177:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/16\">",
"      Iwashima M, Irving BA, van Oers NS, et al. Sequential interactions of the TCR with two distinct cytoplasmic tyrosine kinases. Science 1994; 263:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/17\">",
"      van Oers NS, Tohlen B, Malissen B, et al. The 21- and 23-kD forms of TCR zeta are generated by specific ITAM phosphorylations. Nat Immunol 2000; 1:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/18\">",
"      Weil R, Cloutier JF, Fournel M, Veillette A. Regulation of Zap-70 by Src family tyrosine protein kinases in an antigen-specific T-cell line. J Biol Chem 1995; 270:2791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/19\">",
"      van Oers NS, Killeen N, Weiss A. Lck regulates the tyrosine phosphorylation of the T cell receptor subunits and ZAP-70 in murine thymocytes. J Exp Med 1996; 183:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/20\">",
"      Chan AC, Irving BA, Fraser JD, Weiss A. The zeta chain is associated with a tyrosine kinase and upon T-cell antigen receptor stimulation associates with ZAP-70, a 70-kDa tyrosine phosphoprotein. Proc Natl Acad Sci U S A 1991; 88:9166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/21\">",
"      Cohen S, Dadi H, Shaoul E, et al. Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase, Lyp. Blood 1999; 93:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/22\">",
"      Bottini N, Musumeci L, Alonso A, et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 2004; 36:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/23\">",
"      Wu H, Cantor RM, Graham DS, et al. Association analysis of the R620W polymorphism of protein tyrosine phosphatase PTPN22 in systemic lupus erythematosus families: increased T allele frequency in systemic lupus erythematosus patients with autoimmune thyroid disease. Arthritis Rheum 2005; 52:2396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/24\">",
"      Vang T, Miletic AV, Bottini N, Mustelin T. Protein tyrosine phosphatase PTPN22 in human autoimmunity. Autoimmunity 2007; 40:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/25\">",
"      Nahum A, Bates A, Sharfe N, Roifman CM. Association of the lymphoid protein tyrosine phosphatase, R620W variant, with chronic mucocutaneous candidiasis. J Allergy Clin Immunol 2008; 122:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/26\">",
"      Vang T, Congia M, Macis MD, et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet 2005; 37:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/27\">",
"      Fiorillo E, Orr&uacute; V, Stanford SM, et al. Autoimmune-associated PTPN22 R620W variation reduces phosphorylation of lymphoid phosphatase on an inhibitory tyrosine residue. J Biol Chem 2010; 285:26506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/28\">",
"      Yasuda K, Nagafuku M, Shima T, et al. Cutting edge: Fyn is essential for tyrosine phosphorylation of Csk-binding protein/phosphoprotein associated with glycolipid-enriched microdomains in lipid rafts in resting T cells. J Immunol 2002; 169:2813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/29\">",
"      Davidson D, Bakinowski M, Thomas ML, et al. Phosphorylation-dependent regulation of T-cell activation by PAG/Cbp, a lipid raft-associated transmembrane adaptor. Mol Cell Biol 2003; 23:2017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/30\">",
"      Xu C, Gagnon E, Call ME, et al. Regulation of T cell receptor activation by dynamic membrane binding of the CD3epsilon cytoplasmic tyrosine-based motif. Cell 2008; 135:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/31\">",
"      Arpaia E, Shahar M, Dadi H, et al. Defective T cell receptor signaling and CD8+ thymic selection in humans lacking zap-70 kinase. Cell 1994; 76:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/32\">",
"      Elder ME, Lin D, Clever J, et al. Human severe combined immunodeficiency due to a defect in ZAP-70, a T cell tyrosine kinase. Science 1994; 264:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/33\">",
"      Roifman CM, Hummel D, Martinez-Valdez H, et al. Depletion of CD8+ cells in human thymic medulla results in selective immune deficiency. J Exp Med 1989; 170:2177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/34\">",
"      Roifman CM, Dadi H, Somech R, et al. Characterization of &zeta;-associated protein, 70 kd (ZAP70)-deficient human lymphocytes. J Allergy Clin Immunol 2010; 126:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/35\">",
"      Neumeister EN, Zhu Y, Richard S, et al. Binding of ZAP-70 to phosphorylated T-cell receptor zeta and eta enhances its autophosphorylation and generates specific binding sites for SH2 domain-containing proteins. Mol Cell Biol 1995; 15:3171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/36\">",
"      Wange RL, Malek SN, Desiderio S, Samelson LE. Tandem SH2 domains of ZAP-70 bind to T cell antigen receptor zeta and CD3 epsilon from activated Jurkat T cells. J Biol Chem 1993; 268:19797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/37\">",
"      Isakov N, Wange RL, Burgess WH, et al. ZAP-70 binding specificity to T cell receptor tyrosine-based activation motifs: the tandem SH2 domains of ZAP-70 bind distinct tyrosine-based activation motifs with varying affinity. J Exp Med 1995; 181:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/38\">",
"      Hatada MH, Lu X, Laird ER, et al. Molecular basis for interaction of the protein tyrosine kinase ZAP-70 with the T-cell receptor. Nature 1995; 377:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/39\">",
"      Goldman FD, Ballas ZK, Schutte BC, et al. Defective expression of p56lck in an infant with severe combined immunodeficiency. J Clin Invest 1998; 102:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/40\">",
"      Chan AC, Dalton M, Johnson R, et al. Activation of ZAP-70 kinase activity by phosphorylation of tyrosine 493 is required for lymphocyte antigen receptor function. EMBO J 1995; 14:2499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/41\">",
"      Wange RL, Guiti&aacute;n R, Isakov N, et al. Activating and inhibitory mutations in adjacent tyrosines in the kinase domain of ZAP-70. J Biol Chem 1995; 270:18730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/42\">",
"      Watts JD, Affolter M, Krebs DL, et al. Identification by electrospray ionization mass spectrometry of the sites of tyrosine phosphorylation induced in activated Jurkat T cells on the protein tyrosine kinase ZAP-70. J Biol Chem 1994; 269:29520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/43\">",
"      Kong G, Dalton M, Bubeck Wardenburg J, et al. Distinct tyrosine phosphorylation sites in ZAP-70 mediate activation and negative regulation of antigen receptor function. Mol Cell Biol 1996; 16:5026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/44\">",
"      Gong Q, Jin X, Akk AM, et al. Requirement for tyrosine residues 315 and 319 within zeta chain-associated protein 70 for T cell development. J Exp Med 2001; 194:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/45\">",
"      Katzav S, Sutherland M, Packham G, et al. The protein tyrosine kinase ZAP-70 can associate with the SH2 domain of proto-Vav. J Biol Chem 1994; 269:32579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/46\">",
"      Wu J, Zhao Q, Kurosaki T, Weiss A. The Vav binding site (Y315) in ZAP-70 is critical for antigen receptor-mediated signal transduction. J Exp Med 1997; 185:1877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/47\">",
"      Pelosi M, Di Bartolo V, Mounier V, et al. Tyrosine 319 in the interdomain B of ZAP-70 is a binding site for the Src homology 2 domain of Lck. J Biol Chem 1999; 274:14229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/48\">",
"      Williams BL, Irvin BJ, Sutor SL, et al. Phosphorylation of Tyr319 in ZAP-70 is required for T-cell antigen receptor-dependent phospholipase C-gamma1 and Ras activation. EMBO J 1999; 18:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/49\">",
"      Di Bartolo V, M&egrave;ge D, Germain V, et al. Tyrosine 319, a newly identified phosphorylation site of ZAP-70, plays a critical role in T cell antigen receptor signaling. J Biol Chem 1999; 274:6285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/50\">",
"      Zhao Q, Weiss A. Enhancement of lymphocyte responsiveness by a gain-of-function mutation of ZAP-70. Mol Cell Biol 1996; 16:6765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/51\">",
"      Lupher ML Jr, Songyang Z, Shoelson SE, et al. The Cbl phosphotyrosine-binding domain selects a D(N/D)XpY motif and binds to the Tyr292 negative regulatory phosphorylation site of ZAP-70. J Biol Chem 1997; 272:33140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/52\">",
"      Rao N, Lupher ML Jr, Ota S, et al. The linker phosphorylation site Tyr292 mediates the negative regulatory effect of Cbl on ZAP-70 in T cells. J Immunol 2000; 164:4616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/53\">",
"      Rudd CE. Adaptors and molecular scaffolds in immune cell signaling. Cell 1999; 96:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/54\">",
"      Bubeck Wardenburg J, Fu C, Jackman JK, et al. Phosphorylation of SLP-76 by the ZAP-70 protein-tyrosine kinase is required for T-cell receptor function. J Biol Chem 1996; 271:19641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/55\">",
"      Finco TS, Kadlecek T, Zhang W, et al. LAT is required for TCR-mediated activation of PLCgamma1 and the Ras pathway. Immunity 1998; 9:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/56\">",
"      Yablonski D, Kuhne MR, Kadlecek T, Weiss A. Uncoupling of nonreceptor tyrosine kinases from PLC-gamma1 in an SLP-76-deficient T cell. Science 1998; 281:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/57\">",
"      Yablonski D, Weiss A. Mechanisms of signaling by the hematopoietic-specific adaptor proteins, SLP-76 and LAT and their B cell counterpart, BLNK/SLP-65. Adv Immunol 2001; 79:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/58\">",
"      Zhang W, Sloan-Lancaster J, Kitchen J, et al. LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation. Cell 1998; 92:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/59\">",
"      Donovan JA, Wange RL, Langdon WY, Samelson LE. The protein product of the c-cbl protooncogene is the 120-kDa tyrosine-phosphorylated protein in Jurkat cells activated via the T cell antigen receptor. J Biol Chem 1994; 269:22921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/60\">",
"      June CH, Fletcher MC, Ledbetter JA, Samelson LE. Increases in tyrosine phosphorylation are detectable before phospholipase C activation after T cell receptor stimulation. J Immunol 1990; 144:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/61\">",
"      Sommers CL, Samelson LE, Love PE. LAT: a T lymphocyte adapter protein that couples the antigen receptor to downstream signaling pathways. Bioessays 2004; 26:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/62\">",
"      Raab M, da Silva AJ, Findell PR, Rudd CE. Regulation of Vav-SLP-76 binding by ZAP-70 and its relevance to TCR zeta/CD3 induction of interleukin-2. Immunity 1997; 6:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/63\">",
"      Zhang W, Sommers CL, Burshtyn DN, et al. Essential role of LAT in T cell development. Immunity 1999; 10:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/64\">",
"      Shen S, Zhu M, Lau J, et al. The essential role of LAT in thymocyte development during transition from the double-positive to single-positive stage. J Immunol 2009; 182:5596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/65\">",
"      Liao XC, Littman DR. Altered T cell receptor signaling and disrupted T cell development in mice lacking Itk. Immunity 1995; 3:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/66\">",
"      Perez-Villar JJ, Kanner SB. Regulated association between the tyrosine kinase Emt/Itk/Tsk and phospholipase-C gamma 1 in human T lymphocytes. J Immunol 1999; 163:6435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/67\">",
"      Mano H. Tec family of protein-tyrosine kinases: an overview of their structure and function. Cytokine Growth Factor Rev 1999; 10:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/68\">",
"      Bogin Y, Ainey C, Beach D, Yablonski D. SLP-76 mediates and maintains activation of the Tec family kinase ITK via the T cell antigen receptor-induced association between SLP-76 and ITK. Proc Natl Acad Sci U S A 2007; 104:6638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/69\">",
"      Qi Q, August A. Keeping the (kinase) party going: SLP-76 and ITK dance to the beat. Sci STKE 2007; 2007:pe39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/70\">",
"      Juntilla MM, Koretzky GA. Critical roles of the PI3K/Akt signaling pathway in T cell development. Immunol Lett 2008; 116:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/71\">",
"      Kane LP, Weiss A. The PI-3 kinase/Akt pathway and T cell activation: pleiotropic pathways downstream of PIP3. Immunol Rev 2003; 192:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/72\">",
"      Ebanks R, Roifman C, Mellors A, Mills GB. The diacylglycerol analogue, 1,2-sn-dioctanoylglycerol, induces an increase in cytosolic free Ca2+ and cytosolic acidification of T lymphocytes through a protein kinase C-independent process. Biochem J 1989; 258:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/73\">",
"      Beyersdorf N, Braun A, V&ouml;gtle T, et al. STIM1-independent T cell development and effector function in vivo. J Immunol 2009; 182:3390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/74\">",
"      Melamed I, Stein L, Roifman CM. Epstein-Barr virus induces actin polymerization in human B cells. J Immunol 1994; 153:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/75\">",
"      Dustin ML, Chakraborty AK, Shaw AS. Understanding the structure and function of the immunological synapse. Cold Spring Harb Perspect Biol 2010; 2:a002311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/76\">",
"      Dustin ML. Modular design of immunological synapses and kinapses. Cold Spring Harb Perspect Biol 2009; 1:a002873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/77\">",
"      Fooksman DR, Vardhana S, Vasiliver-Shamis G, et al. Functional anatomy of T cell activation and synapse formation. Annu Rev Immunol 2010; 28:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/78\">",
"      Sims TN, Soos TJ, Xenias HS, et al. Opposing effects of PKCtheta and WASp on symmetry breaking and relocation of the immunological synapse. Cell 2007; 129:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/79\">",
"      Sykulev Y. T cell receptor signaling kinetics takes the stage. Sci Signal 2010; 3:pe50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/80\">",
"      Villa A, Santagata S, Bozzi F, et al. Partial V(D)J recombination activity leads to Omenn syndrome. Cell 1998; 93:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/81\">",
"      Brockmeyer C, Paster W, Pepper D, et al. T cell receptor (TCR)-induced tyrosine phosphorylation dynamics identifies THEMIS as a new TCR signalosome component. J Biol Chem 2011; 286:7535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/82\">",
"      Colucci F, Schweighoffer E, Tomasello E, et al. Natural cytotoxicity uncoupled from the Syk and ZAP-70 intracellular kinases. Nat Immunol 2002; 3:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/83\">",
"      Palacios EH, Weiss A. Distinct roles for Syk and ZAP-70 during early thymocyte development. J Exp Med 2007; 204:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/84\">",
"      Chu DH, van Oers NS, Malissen M, et al. Pre-T cell receptor signals are responsible for the down-regulation of Syk protein tyrosine kinase expression. J Immunol 1999; 163:2610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/85\">",
"      Elder ME, Skoda-Smith S, Kadlecek TA, et al. Distinct T cell developmental consequences in humans and mice expressing identical mutations in the DLAARN motif of ZAP-70. J Immunol 2001; 166:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/86\">",
"      Wiest DL, Ashe JM, Howcroft TK, et al. A spontaneously arising mutation in the DLAARN motif of murine ZAP-70 abrogates kinase activity and arrests thymocyte development. Immunity 1997; 6:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/87\">",
"      Goldrath AW, Bevan MJ. Selecting and maintaining a diverse T-cell repertoire. Nature 1999; 402:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/88\">",
"      Anderson MS, Su MA. Aire and T cell development. Curr Opin Immunol 2011; 23:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/89\">",
"      Akirav EM, Ruddle NH, Herold KC. The role of AIRE in human autoimmune disease. Nat Rev Endocrinol 2011; 7:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/90\">",
"      Chan AC, van Oers NS, Tran A, et al. Differential expression of ZAP-70 and Syk protein tyrosine kinases, and the role of this family of protein tyrosine kinases in TCR signaling. J Immunol 1994; 152:4758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/91\">",
"      Williams BL, Schreiber KL, Zhang W, et al. Genetic evidence for differential coupling of Syk family kinases to the T-cell receptor: reconstitution studies in a ZAP-70-deficient Jurkat T-cell line. Mol Cell Biol 1998; 18:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/92\">",
"      Noraz N, Schwarz K, Steinberg M, et al. Alternative antigen receptor (TCR) signaling in T cells derived from ZAP-70-deficient patients expressing high levels of Syk. J Biol Chem 2000; 275:15832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/93\">",
"      Toyabe S, Watanabe A, Harada W, et al. Specific immunoglobulin E responses in ZAP-70-deficient patients are mediated by Syk-dependent T-cell receptor signalling. Immunology 2001; 103:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/94\">",
"      Cheng AM, Negishi I, Anderson SJ, et al. The Syk and ZAP-70 SH2-containing tyrosine kinases are implicated in pre-T cell receptor signaling. Proc Natl Acad Sci U S A 1997; 94:9797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/95\">",
"      Lesourne R, Uehara S, Lee J, et al. Themis, a T cell-specific protein important for late thymocyte development. Nat Immunol 2009; 10:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/96\">",
"      Fu G, Vall&eacute;e S, Rybakin V, et al. Themis controls thymocyte selection through regulation of T cell antigen receptor-mediated signaling. Nat Immunol 2009; 10:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/97\">",
"      Brumbaugh KM, Binstadt BA, Billadeau DD, et al. Functional role for Syk tyrosine kinase in natural killer cell-mediated natural cytotoxicity. J Exp Med 1997; 186:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/98\">",
"      Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. Nat Rev Immunol 2001; 1:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/26/25001/abstract/99\">",
"      Elder ME, Hope TJ, Parslow TG, et al. Severe combined immunodeficiency with absence of peripheral blood CD8+ T cells due to ZAP-70 deficiency. Cell Immunol 1995; 165:110.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15794 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-4E972C53F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_26_25001=[""].join("\n");
var outline_f24_26_25001=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11026616\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11026511\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11026518\">",
"      BRIEF OVERVIEW OF THE SIGNALING CASCADE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11026525\">",
"      EARLY SIGNAL TRANSDUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11026532\">",
"      Lck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11026539\">",
"      ZAP-70",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11026546\">",
"      DISTAL CASCADE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11026553\">",
"      LAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11026560\">",
"      Lipid and lipid derived messengers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11026567\">",
"      Calcium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11026574\">",
"      Actin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11026581\">",
"      TCR SIGNALING IN T CELL ONTOGENY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11026588\">",
"      Syk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11026595\">",
"      Themis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11026602\">",
"      NK CELL SIGNALING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11026609\">",
"      CORECEPTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11026616\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/15794\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/15794|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/20/20807\" title=\"figure 1\">",
"      T cell receptor signaling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/18/34083\" title=\"figure 2\">",
"      Early events Tcell transduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/33/22047\" title=\"figure 3\">",
"      Scheme thymic T cell development",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25432?source=related_link\">",
"      Antigen presenting cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28329?source=related_link\">",
"      CD3/T cell receptor complex disorders causing immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22553?source=related_link\">",
"      Chronic mucocutaneous candidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=related_link\">",
"      Combined immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30009?source=related_link\">",
"      Idiopathic CD4+ lymphocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30889?source=related_link\">",
"      NK cell deficiency syndromes: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/39/4724?source=related_link\">",
"      NK cell deficiency syndromes: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/0/10?source=related_link\">",
"      Severe combined immunodeficiency (SCID): Specific defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20362?source=related_link\">",
"      T cell negative, B cell negative, NK cell positive severe combined immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37733?source=related_link\">",
"      T cell receptor genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=related_link\">",
"      The adaptive cellular immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36313?source=related_link\">",
"      Wiskott-Aldrich syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42022?source=related_link\">",
"      ZAP-70 deficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_26_25002="Pityriasis lichenoides et varioliformis acuta";
var content_f24_26_25002=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F57911%7EDERM%2F83096%7EDERM%2F85773&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F57911%7EDERM%2F83096%7EDERM%2F85773&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pityriasis lichenoides et varioliformis acuta",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple inflammatory papules are present. Some lesions demonstrate necrosis and crusting.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pityriasis lichenoides et varioliformis acuta (PLEVA)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pityriasis lichenoides et varioliformis acuta (PLEVA)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous papules and papulovesicles are present on the thigh. Postinflammatory hyperpigmentation is evident at sites of previous lesions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_26_25002=[""].join("\n");
var outline_f24_26_25002=null;
var title_f24_26_25003="Risk of placental abnormality by number of cesareans";
var content_f24_26_25003=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk of placenta previa and accreta according to number of previous cesarean deliveries",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Number of cesareans",
"      </td>",
"      <td class=\"subtitle1\">",
"       Previa (percent)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Accreta (percent)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Accreta in patients with previa (percent)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Two",
"      </td>",
"      <td>",
"       1.33",
"      </td>",
"      <td>",
"       0.31",
"      </td>",
"      <td>",
"       11",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Three",
"      </td>",
"      <td>",
"       1.14",
"      </td>",
"      <td>",
"       0.57",
"      </td>",
"      <td>",
"       40",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Four",
"      </td>",
"      <td>",
"       2.27",
"      </td>",
"      <td>",
"       2.13",
"      </td>",
"      <td>",
"       61",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Five",
"      </td>",
"      <td>",
"       2.33",
"      </td>",
"      <td>",
"       2.33",
"      </td>",
"      <td>",
"       67",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Six or more",
"      </td>",
"      <td>",
"       3.37",
"      </td>",
"      <td>",
"       6.74",
"      </td>",
"      <td>",
"       67",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The baseline risk of placenta previa in the general obstetrical population is one in 200 deliveries. Placenta accreta occurs in fewer than one in 500 deliveries.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Silver, RM, Landon, MB, Rouse, DJ, et al. Obstet Gynecol 2006; 107:1226.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_26_25003=[""].join("\n");
var outline_f24_26_25003=null;
var title_f24_26_25004="Dose adj prevention GVHD";
var content_f24_26_25004=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F79917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F79917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dose adjustments for methotrexate and cyclosporine when used for the prevention of graft-versus-host disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Methotrexate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Serum bilirubin, mg/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        &lt;2.0",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        2.1-3.0",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        3.1-5.0",
"       </td>",
"       <td>",
"        25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        &gt;5.0",
"       </td>",
"       <td>",
"        <strong>",
"         HOLD",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\" rowspan=\"1\">",
"        Serum creatinine mg/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        &lt;1.5",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1.5-1.7",
"       </td>",
"       <td>",
"        75",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1.8-2.0",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        &gt;2.0",
"       </td>",
"       <td>",
"        <strong>",
"         HOLD",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        NOTE: in",
"order to ensure methotrexate excretion, please be sure that the urine",
"is alkalinized with a pH above 8.0 prior to therapy. This can be",
"achieved by the administration of sodium bicarbonate. The serum",
"methotrexate concentration should be measured at least after the third",
"or fourth dose to ensure that methotrexate excretion is adequate.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Cyclosporine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\" rowspan=\"1\">",
"        Serum creatinine, mg/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        &lt;1.5",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1.5-1.7",
"       </td>",
"       <td>",
"        75",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1.8-2.0",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        &gt;2.0",
"       </td>",
"       <td>",
"        <strong>",
"         HOLD*",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Restart cyclosporine at 40 to 80 mg IV QD (or 50 to 100 mg PO BID) when the serum creatinine concentration falls below 2.0 mg/dL (177 &micro;mol/L) and then increase gradually to the desired dose as tolerated.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_26_25004=[""].join("\n");
var outline_f24_26_25004=null;
var title_f24_26_25005="CF nutrition monitor";
var content_f24_26_25005=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nutritional assessment during routine care at a Cystic Fibrosis center",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       At diagnosis",
"      </td>",
"      <td class=\"subtitle1\">",
"       Every 3 months birth to 24 months",
"      </td>",
"      <td class=\"subtitle1\">",
"       Every 3 months",
"      </td>",
"      <td class=\"subtitle1\">",
"       Annually",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Head circumference",
"      </td>",
"      <td>",
"       X*",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Weight (to 0.1 kg)",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Length (to 0.1 cm)",
"      </td>",
"      <td>",
"       X*",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Height (to 0.1 cm)",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Weight for length (birth to 24 mo)",
"      </td>",
"      <td>",
"       X*",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       BMI percentile (24 mo to adult)",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mid-arm circumference (to 0.1 cm)",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       X",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Triceps skinfold (to 1.0 mm)",
"      </td>",
"      <td>",
"       X&bull;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       X",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mid-arm muscle area, mm",
"       <sup>",
"        2",
"       </sup>",
"       (calculated from MAC and TSF)",
"      </td>",
"      <td>",
"       X&bull;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       X",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mid-arm fat area, mm",
"       <sup>",
"        2",
"       </sup>",
"       (calculated from MAC and TSF)",
"      </td>",
"      <td>",
"       X&bull;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       X",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Biological parents height&Delta;",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pubertal status, female",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       X&loz;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pubertal status, male",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       X&sect;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       24-hour diet recall",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       X",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nutritional supplement intake&yen;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       X",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Anticipatory dietary and feeding behavior guidance",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       X",
"      </td>",
"      <td>",
"       X&Dagger;",
"      </td>",
"      <td>",
"       X",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MAC: Mid-arm circumference; TSF: Triceps skinfold.",
"     <br>",
"      * If less than 24 months of age at diagnosis.",
"      <br>",
"       &bull; Only in patients over 1 year of age.",
"       <br>",
"        &Delta; Record in cm and gender-specific height percentile; note patient's target height percentile on all growth charts.",
"        <br>",
"         &loz; Starting at age 9 years, annual pubertal self-assessment form (patient, or parent and patient) or physician examination for breast and pubic hair, Tanner stage determination; annual question as to menarchal status. Record month and year of menarche on all growth charts.",
"         <br>",
"          &sect; Starting at age 10 years, annual pubertal self-assessment form (patient, or parent and patient) or physician examination for genital development and pubic hair, Tanner stage determination.",
"          <br>",
"           &yen; A review of enzymes, vitamins, minerals, oral or enteral formulas; herbal, botanical, and other Complimentary and Alternative Medicine products.",
"           <br>",
"            ������ Routine surveillance may be done informally by other team members, but the annual assessment and q 3 monthly visits in the first 2 years of life and q 3 monthly visits for patients at nutritional risk should be done by the center dietician.",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2002; 35:246. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_26_25005=[""].join("\n");
var outline_f24_26_25005=null;
var title_f24_26_25006="Contents: Neuroophthalmology";
var content_f24_26_25006=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?0/63/1022\">",
"       Neurology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Neuroophthalmology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Neuroophthalmology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Cranial neuropathies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/30/31206\">",
"           Approach to the patient with anisocoria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/19/32057\">",
"           Approach to the patient with vertigo",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/23/36216\">",
"           Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/27/9655\">",
"           Bell's palsy: Prognosis and treatment in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/13/19673\">",
"           Benign paroxysmal positional vertigo",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/32/32262\">",
"           Horner's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/49/20246\">",
"           Internuclear ophthalmoplegia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/15/9464\">",
"           Optic neuritis: Pathophysiology, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/15/29944\">",
"           Optic neuritis: Prognosis and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/54/4969\">",
"           Optic neuropathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/53/30552\">",
"           Overview and differential diagnosis of papilledema",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/46/25320\">",
"           Overview of diplopia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/33/31255\">",
"           Overview of ptosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/63/36856\">",
"           Third cranial nerve (oculomotor nerve) palsy in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/5/44117\">",
"           Tonic pupil",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/15/13559\">",
"           Treatment of vertigo",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/36/42569\">",
"           Approach to the patient with visual hallucinations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/0/17417\">",
"           Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/25/15769\">",
"           Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/54/41833\">",
"           Idiopathic intracranial hypertension (pseudotumor cerebri): Prognosis and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/53/7001\">",
"           Ocular myasthenia gravis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/28/24006\">",
"           Tolosa-Hunt syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/7/32886\">",
"           Visual release hallucinations (Charles Bonnet syndrome)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Specific disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/48/30473\">",
"           Carotid-cavernous fistulas",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vertigo and nystagmus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/19/32057\">",
"           Approach to the patient with vertigo",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/13/19673\">",
"           Benign paroxysmal positional vertigo",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/6/23658\">",
"           Jerk nystagmus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/23/34165\">",
"           Overview of nystagmus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/38/17001\">",
"           Pathophysiology, etiology, and differential diagnosis of vertigo",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/0/1034\">",
"           Pendular nystagmus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/15/13559\">",
"           Treatment of vertigo",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/15/35062\">",
"           Vestibular neuritis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vision loss",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/26/10666\">",
"           Amaurosis fugax (transient monocular or binocular visual loss)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/50/3882\">",
"           Central and branch retinal artery occlusion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/16/44293\">",
"           Diabetic papillopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/61/37848\">",
"           Homonymous hemianopia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/58/27558\">",
"           Nonarteritic anterior ischemic optic neuropathy: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/61/20442\">",
"           Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/44/9929\">",
"           Nonarteritic ischemic optic neuropathy: Prognosis and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/15/9464\">",
"           Optic neuritis: Pathophysiology, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/15/29944\">",
"           Optic neuritis: Prognosis and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/54/4969\">",
"           Optic neuropathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/6/35943\">",
"           Posterior ischemic optic neuropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/7/32886\">",
"           Visual release hallucinations (Charles Bonnet syndrome)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-D16BFFA211-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f24_26_25006=[""].join("\n");
var outline_f24_26_25006=null;
var title_f24_26_25007="CSF cytology in a patient with adenocarcinoma of the lung";
var content_f24_26_25007=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F55757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F55757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    CSF cytology in a patient with adenocarcinoma of the lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 348px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The two cells seen in this figure are carcinoma cells that establish the diagnosis of leptomeningeal metastases.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Alexis Demopoulos, MD, and Jerome Posner, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_26_25007=[""].join("\n");
var outline_f24_26_25007=null;
